

REFINITIV

DELTA REPORT

10-Q

HYFM - HYDROFARM HOLDINGS GROUP,
10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	1430
CHANGES	174
DELETIONS	481
ADDITIONS	775

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, 2023** **March 31, 2024**
OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For transition period from to
Commission File Number: 001-39773

Hydrofarm Holdings Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware

81-4895761

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification Number)

1510 Main Street
Shoemakersville, Pennsylvania 19555
(707) 765-9990

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol</u>	<u>Name of each exchange on which registered</u>
Common Stock, \$0.0001 par value per share	HYFM	Nasdaq Global Select Stock Market LLC

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\$32.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input checked="" type="checkbox"/> <input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/> <input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

As of **October 31, 2023** **May 7, 2024**, the registrant had **45,759,575** **45,978,795** shares of common stock, \$0.0001 par value per share, outstanding.

[TABLE OF CONTENTS](#)

TABLE OF CONTENTS

	Page
<u>Part I - Financial Information</u>	
Item 1. Financial Statements	1
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations	2
Condensed Consolidated Statements of Comprehensive Loss	3
Condensed Consolidated Statements of Changes in Stockholders' Equity	4
Condensed Consolidated Statements of Cash Flows	5
Notes to the Condensed Consolidated Financial Statements	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	27 23
Item 3. Quantitative and Qualitative Disclosures About Market Risk	35 29
Item 4. Controls and Procedures	36 30
<u>Part II - Other Information</u>	
Item 1. Legal Proceedings	37 31
Item 1A. Risk Factors	37 31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	38 31
Item 3. Defaults Upon Senior Securities	38 31
Item 4. Mine Safety Disclosures	38 31
Item 5. Other Information	38 32
Item 6. Exhibits	39 33
Signatures	40 34

[TABLE OF CONTENTS](#)

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.

In some cases, you can identify forward-looking statements by such terminology as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements about:

- industry conditions, including oversupply and decreasing prices of our customers' products which, in turn, **has have** materially adversely impacted our sales and other results of operations and which may continue to do so in the future;
- the potential for future charges associated with the impairment of our long-lived assets, inventory allowances and purchase commitment losses, and accounts receivable reserves;
- our liquidity;
- our ability to meet the continued listing standards of **Nasdaq; The Nasdaq Capital Market ("Nasdaq");**
- **the impact of** our restructuring activities **may increase on** our expenses and cash **expenditures, and may not have the intended cost saving effects; expenditures;**
- potential dilution that may result from equity financings while our stock prices are depressed;

- general economic and financial conditions, specifically in the United States and Canada;
- the conditions impacting our customers, including related crop prices and other factors impacting growers;
- the adverse effects of public health epidemics, including the COVID-19 pandemic, on our business, results of operations and financial condition;
- interruptions in our supply chain;
- federal and state legislation and regulations pertaining to the use and cultivation of cannabis in the United States and Canada;
- public perceptions and acceptance of cannabis use;
- fluctuations in the price of various crops and other factors affecting growers;
- the results of our acquisitions and strategic alliances;
- our long-term non-cancellable leases under which many of our facilities operate, and our ability to renew or terminate our leases;
- our reliance on, and relationships with, a limited base of key suppliers for certain products;
- our ability to keep pace with technological advances;
- our ability to execute our e-commerce business;
- the costs of being a public company;
- our ability to successfully identify appropriate acquisition targets, successfully acquire identified targets or successfully integrate the business of acquired companies;
- the success of our marketing activities;
- a disruption or breach of our information technology systems or cyber-attack;
- our current level of indebtedness;
- our dependence on third parties;
- any change to our reputation or to the reputation of our products;
- the performance of third parties on which we depend;
- the fluctuation in the prices of the products we distribute;

[TABLE OF CONTENTS](#)

- competitive industry pressures;
- the consolidation of our industry;
- compliance with environmental, health and safety laws;
- our ability to protect and defend against litigation, including claims related to intellectual property and proprietary rights;
- product shortages and relationships with key suppliers;
- our ability to attract and retain key employees;
- the volatility of the price of our common stock;
- the marketability of our common stock; and
- other risks and uncertainties, including those listed herein as well as under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on **March 9, 2023** **February 29, 2024** (the **"2022"** **"2023"** Annual Report).

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ

materially from those projected in the forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements for any reason or to conform such statements to actual results or revised expectations, except as required by law.

"Hydrofarm" and other trade names and trademarks of ours appearing in this Quarterly Report on Form 10-Q are our property. This Quarterly Report on Form 10-Q contains trade names and trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies' trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.

Unless the context otherwise indicates, references in this Quarterly Report on Form 10-Q to the terms "Hydrofarm", "the Company," "we," "our" and "us" refer to Hydrofarm Holdings Group, Inc. and its subsidiaries.

[TABLE OF CONTENTS](#)

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share and per share amounts)

		September 30, 2023	December 31, 2022		
		March 31, 2024		March 31, 2024	December 31, 2023
Assets	Assets				
Current assets:	Current assets:				
Current assets:					
Current assets:					
Cash and cash equivalents	Cash and cash equivalents	\$ 32,457	\$ 21,291		
Cash and cash equivalents					
Cash and cash equivalents					
Accounts receivable, net	Accounts receivable, net	17,070	17,227		
Inventories	Inventories	80,101	111,398		
Prepaid expenses and other current assets	Prepaid expenses and other current assets	4,272	5,032		
Total current assets	Total current assets	133,900	154,948		
Property, plant and equipment, net	Property, plant and equipment, net	48,119	51,135		
Operating lease right-of-use assets	Operating lease right-of-use assets	56,655	65,265		
Intangible assets, net	Intangible assets, net	281,990	300,366		
Other assets	Other assets	1,766	1,845		
Total assets	Total assets	\$ 522,430	\$573,559		

Liabilities and stockholders' equity	Liabilities and stockholders' equity			
Current liabilities:	Current liabilities:			
Current liabilities:				
Accounts payable				
Accounts payable				
Accounts payable	Accounts payable	\$	13,028	\$ 13,633
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities		8,023	13,208
Deferred revenue	Deferred revenue		3,564	3,654
Current portion of operating lease liabilities	Current portion of operating lease liabilities		8,505	9,099
Current portion of finance lease liabilities	Current portion of finance lease liabilities		974	704
Current portion of long-term debt	Current portion of long-term debt		1,295	1,307
Total current liabilities	Total current liabilities		35,389	41,605
Long-term operating lease liabilities	Long-term operating lease liabilities		49,843	56,299
Long-term finance lease liabilities	Long-term finance lease liabilities		8,956	1,200
Long-term debt	Long-term debt		117,169	117,461
Deferred tax liabilities	Deferred tax liabilities		2,684	2,685
Other long-term liabilities	Other long-term liabilities		4,465	4,428
Total liabilities	Total liabilities		218,506	223,678
Commitments and contingencies (Note 13)	Commitments and contingencies (Note 13)			
Stockholders' equity	Stockholders' equity			
Common stock (\$0.0001 par value; 300,000,000 shares authorized; 45,688,695 and 45,197,249 shares issued and outstanding at September 30, 2023, and December 31, 2022, respectively)			5	5
Common stock (\$0.0001 par value; 300,000,000 shares authorized; 45,977,935 and 45,789,890 shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively)				

Common stock (\$0.0001 par value;
300,000,000 shares authorized;
45,977,935 and 45,789,890
shares issued and outstanding at
March 31, 2024, and December
31, 2023, respectively)

Common stock (\$0.0001 par value;
300,000,000 shares authorized;
45,977,935 and 45,789,890
shares issued and outstanding at
March 31, 2024, and December
31, 2023, respectively)

Additional paid-in capital	Additional paid-in capital	786,829	783,042
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(7,381)	(7,235)
Accumulated deficit	Accumulated deficit	(475,529)	(425,931)
Total stockholders' equity	Total stockholders' equity	303,924	349,881
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	\$ 522,430	\$573,559

The accompanying notes are an integral part of the condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In thousands, except share and per share amounts)

		Three months ended September 30,		Nine months ended September 30,	
		2023	2022	2023	2022
Three months ended March 31,			Three months ended March 31,		
2024			2024		
Net sales	Net sales	\$ 54,168	\$ 74,155	\$ 179,397	\$ 283,040
Cost of goods sold	Cost of goods sold	50,859	68,291	150,234	253,231
Gross profit	Gross profit	3,309	5,864	29,163	29,809
Operating expenses:	Operating expenses:				
Selling, general and administrative	Selling, general and administrative	19,543	26,186	67,442	92,407
Impairments	Impairments	—	—	—	192,328
Selling, general and administrative	Selling, general and administrative				
Selling, general and administrative	Selling, general and administrative				

Loss from operations	Loss from operations	(16,234)	(20,322)	(38,279)	(254,926)
Interest expense	Interest expense	(3,963)	(3,073)	(11,423)	(7,863)
Other income, net	Other income, net	402	615	22	971
Loss before tax	Loss before tax	(19,795)	(22,780)	(49,680)	(261,818)
Income tax (expense) benefit		(89)	(759)	82	11,671
Income tax expense					
Net loss	Net loss	\$ (19,884)	\$ (23,539)	\$ (49,598)	\$ (250,147)
Net loss per share:	Net loss per share:				
Net loss per share:					
Net loss per share:					
Basic					
Basic					
Basic	Basic	\$ (0.44)	\$ (0.52)	\$ (1.09)	\$ (5.57)
Diluted	Diluted	\$ (0.44)	\$ (0.52)	\$ (1.09)	\$ (5.57)
Weighted-average shares of common stock outstanding:	Weighted-average shares of common stock outstanding:				
Basic	Basic	45,607,195	45,089,286	45,429,139	44,907,355
Basic					
Basic					
Diluted	Diluted	45,607,195	45,089,286	45,429,139	44,907,355

The accompanying notes are an integral part of the condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

(In thousands)

		Three months ended September 30,		Nine months ended September 30,	
		2023	2022	2023	2022
Three months ended March 31,		Three months ended March 31,			
2024		2024			
Net loss	Net loss	\$(19,884)	\$(23,539)	\$(49,598)	\$(250,147)
Other comprehensive loss:	Other comprehensive loss:				
Foreign currency translation loss		(1,686)	(4,714)	(146)	(6,885)
Foreign currency translation (loss) gain					
Foreign currency translation (loss) gain					

The accompanying notes are an integral part of the condensed consolidated financial statements.

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)

(In thousands, except for share amounts)

REFINITIV CORPORATE DISCLOSURES | www.refinitiv.com | Contact Us

Shares repurchased for withholding tax on stock awards	Shares repurchased for withholding tax on stock awards	(45,410)	—	(149)	—	—	(149)
Stock-based compensation expense	Stock-based compensation expense	—	—	1,668	—	—	1,668
Net loss	Net loss	—	—	—	—	(23,539)	(23,539)
Foreign currency translation loss	Foreign currency translation loss	—	—	—	(4,714)	—	(4,714)
Balance, September 30, 2022		45,125,768	\$ 5	\$781,430	\$ (8,267)	\$(390,663)	\$ 382,505
Balance, June 30, 2023		45,540,217	\$ 5	\$785,893	\$ (5,695)	\$(455,645)	\$ 324,558
Issuance of common stock for vesting of stock awards		226,685	—	—	—	—	—
Shares repurchased for withholding tax on stock awards		(78,207)	—	(86)	—	—	(86)
Stock-based compensation expense		—	—	1,022	—	—	1,022
Net loss		—	—	—	—	(19,884)	(19,884)
Foreign currency translation loss		—	—	—	(1,686)	—	(1,686)
Balance, September 30, 2023		45,688,695	\$ 5	\$786,829	\$ (7,381)	\$(475,529)	\$ 303,924
Balance, March 31, 2024							

The accompanying notes are an integral part of the condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)

(In thousands, except for share amounts)

	Common Stock		Additional	Accumulated		Total
	Shares	Amount	Paid-In	Other	Accumulated	Stockholders'
			Capital	Comprehensive	Deficit	Equity
				Loss		
Balance, January 1, 2022	44,618,357	\$ 4	\$ 777,074	\$ (1,382)	\$ (140,516)	\$ 635,180
Common stock issued upon exercise of options	8,283	—	75	—	—	75
Issuance of common stock for vesting of stock awards	699,704	1	—	—	—	1
Shares repurchased for withholding tax on stock awards	(200,675)	—	(2,368)	—	—	(2,368)
Issuance of common stock under cashless warrant exercise	99	—	—	—	—	—
Stock-based compensation expense	—	—	6,649	—	—	6,649
Net loss	—	—	—	—	(250,147)	(250,147)
Foreign currency translation loss	—	—	—	(6,885)	—	(6,885)
Balance, September 30, 2022	45,125,768	\$ 5	\$ 781,430	\$ (8,267)	\$ (390,663)	\$ 382,505
Balance, January 1, 2023	45,197,249	\$ 5	\$ 783,042	\$ (7,235)	\$ (425,931)	\$ 349,881

Issuance of common stock for vesting of stock awards	665,012	—	—	—	—	—
Shares repurchased for withholding tax on stock awards	(173,566)	—	(234)	—	—	(234)
Stock-based compensation expense	—	—	4,021	—	—	4,021
Net loss	—	—	—	—	(49,598)	(49,598)
Foreign currency translation loss	—	—	—	(146)	—	(146)
Balance, September 30, 2023	45,688,695	\$ 5	\$ 786,829	\$ (7,381)	\$ (475,529)	\$ 303,924

The accompanying notes are an integral part of the condensed consolidated financial statements

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)

(Page 1 of 2)

	Nine months ended September 30,	
	2023	2022
Operating activities		
Net loss	\$ (49,598)	\$ (250,147)
Adjustments to reconcile net loss to net cash from operating activities:		
Depreciation, depletion and amortization	24,165	33,215
Provision for inventory obsolescence	1,132	16,348
Restructuring expenses	8,443	—
Stock-based compensation expense	4,021	6,649
Non-cash operating lease expense	7,718	7,275
Impairment charges	—	192,328
Change in fair value of contingent consideration	—	(1,560)
Deferred income tax benefit	—	(12,387)
Other	1,089	1,064
Changes in assets and liabilities:		
Accounts receivable	183	13,135
Inventories	22,566	37,146
Prepaid expenses and other current assets	1,174	(42)
Other assets	(164)	(76)
Accounts payable	(542)	(6,542)
Accrued expenses and other current liabilities	(4,419)	(4,462)
Deferred revenue	(87)	(10,971)
Lease liabilities	(6,972)	(5,328)
Other long-term liabilities	(80)	(155)
Net cash from operating activities	8,629	15,490

Continued on next page

The accompanying notes are an integral part of the condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)

		Nine months ended September 30,	
		2023	2022
Three months ended March 31,		Three months ended March 31,	
2024		2024	2023
Operating activities			
Net loss			
Net loss			
Net loss			
Adjustments to reconcile net loss to net cash from operating activities:			
Depreciation, depletion and amortization			
Depreciation, depletion and amortization			
Depreciation, depletion and amortization			
Provision for (benefit from) doubtful accounts			
Provision for inventory obsolescence			
Restructuring expenses			
Stock-based compensation expense			
Non-cash operating lease expense			
Other			
Changes in assets and liabilities:			
Accounts receivable			
Accounts receivable			
Accounts receivable			
Inventories			
Prepaid expenses and other current assets			
Other assets			
Accounts payable			
Accrued expenses and other current liabilities			

Deferred revenue			
Lease liabilities			
Other long-term liabilities			
Net cash used in operating activities			
Investing activities	Investing activities		
Business combinations, net of cash and cash equivalents			
		—	190
Capital expenditures of property, plant and equipment			
Capital expenditures of property, plant and equipment			
Capital expenditures of property, plant and equipment	Capital expenditures of property, plant and equipment	(4,056)	(7,113)
Other	Other	(2)	(463)
Net cash used in investing activities	Net cash used in investing activities	(4,058)	(7,386)
Financing activities	Financing activities		
Proceeds from Sale-Leaseback Transaction			
Proceeds from Sale-Leaseback Transaction	Proceeds from Sale-Leaseback Transaction	8,598	—
Proceeds from Sale-Leaseback Transaction			
Proceeds from Sale-Leaseback Transaction			
Borrowings under foreign revolving credit facilities	Borrowings under foreign revolving credit facilities	753	773
Repayments of foreign revolving credit facilities	Repayments of foreign revolving credit facilities	(778)	(891)
Repayments of Term Loan	Repayments of Term Loan	(938)	(938)
Payment of withholding tax related to stock awards	Payment of withholding tax related to stock awards	(234)	(2,381)
Payments to settle contingent consideration		—	(15,574)
Other		(757)	(469)

Net cash from (used in) financing activities	6,644	(19,480)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(49)	(515)
Net increase (decrease) in cash, cash equivalents and restricted cash	11,166	(11,891)
Cash, cash equivalents and restricted cash at beginning of period	21,291	28,384
Cash, cash equivalents and restricted cash at end of period	\$32,457	\$16,493
Finance lease principal payments		
Net cash (used in) from financing activities		
Effect of exchange rate changes on cash and cash equivalents		
Net decrease in cash and cash equivalents		
Cash and cash equivalents cash at beginning of period		
Cash and cash equivalents at end of period		
Non-cash investing and financing activities	Non-cash investing and financing activities	
Right-of-use assets (relinquished) acquired under operating lease obligations	\$ (768)	\$10,991
Non-cash investing and financing activities		
Non-cash investing and financing activities		
Right-of-use assets relinquished under operating lease obligations		
Right-of-use assets relinquished under operating lease obligations		
Right-of-use assets relinquished under operating lease obligations		

Assets acquired under finance lease obligations	Assets acquired under finance lease obligations	185	160
Capital expenditures included in accounts payable and accrued liabilities			
Supplemental information	Supplemental information		
Cash paid for interest	Cash paid for interest	10,519	6,860
Cash (refunds) paid for income taxes		(1,039)	3,577
Cash paid for interest			
Cash paid for interest			
Cash paid for income taxes			

The accompanying notes are an integral part of the condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(dollars in thousands, except share and per share amounts)

1. DESCRIPTION OF THE BUSINESS

Description of the business

Hydrofarm Holdings Group, Inc. (collectively with its subsidiaries, the "Company") was formed in May 2017 under the laws of the state of Delaware to acquire and continue the business originally founded in 1977. The Company is a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture ("CEA"), including grow lights, climate control solutions, growing media and nutrients, as well as a broad portfolio of innovative and proprietary branded products. Products offered include agricultural lighting devices, indoor climate control equipment, nutrients, and plant additives used to grow, farm and cultivate cannabis, flowers, fruits, plants, vegetables, grains and herbs in controlled environment settings that allow end users to control key farming variables including temperature, humidity, CO₂, light intensity and color, nutrient concentration and pH.

2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and the requirements of the SEC U.S. Securities and Exchange Commission ("SEC") for interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the Company's annual consolidated financial statements and, in the opinion of management, reflect all normal and recurring adjustments which are necessary for the fair statement of the Company's financial information. The Company reclassified balances of \$704 and \$1,200 as of December 31, 2022, previously reported in "Current portion of long-term debt" and "Long-term debt", respectively, into "Current portion of finance lease liabilities" and "Long-term finance lease liabilities", respectively, on consolidated balance sheet as of December 31, 2022, to conform to the current period presentation. These interim results are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2023 December 31, 2024, or for any other interim period or for any other future year. All intercompany balances and transactions have been eliminated in consolidation.

The condensed consolidated balance sheet as of December 31, 2022 December 31, 2023, has been derived from the audited consolidated financial statements of the Company, which is included in the 2022 2023 Annual Report. These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto included in the 2022 2023 Annual Report.

Use of estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include provisions for sales returns, rebates and claims from customers, realization of accounts receivable and inventories, fair value of assets acquired and liabilities assumed for business combinations, valuation of intangible assets, estimated useful lives of long-lived assets, incremental borrowing rate applied in lease accounting, valuation of stock-based compensation, recognition of deferred income taxes, classification of debt pursuant to certain terms in **our the Company's** credit agreements, recognition of liabilities related to commitments and contingencies, **asset retirement obligations**, and valuation allowances. Actual results may differ from these estimates. On an ongoing basis, the Company reviews its estimates to ensure that these estimates appropriately reflect changes in its business or new information available.

Business combinations Restructuring

Acquisitions of businesses are accounted for using the acquisition method. The **consideration transferred** Company began a restructuring plan (the "Restructuring Plan") in a business combination is measured at fair value, which is calculated as the **sum 2022**, and undertook significant actions to streamline operations, reduce costs and improve efficiencies. The major initiatives of the acquisition date fair values first phase of the assets transferred, liabilities incurred Restructuring Plan included (i) narrowing the Company's product and brand portfolio and (ii) the relocation and consolidation of certain manufacturing and distribution centers, including headcount reductions and reorganization to drive a solution based approach. During the three months ended March 31, 2023, the Company recorded pre-tax expense of \$1,411 relating primarily to the **former owners relocation and termination of the acquiree, and the equity interests issued certain facilities in exchange for control** Canada, which are primarily cash charges. The Company incurred \$327 of **the acquiree**. Acquisition related costs are recognized in net loss as incurred.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

When the consideration transferred in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition date fair value and included as part of the consideration transferred in a business combination. Contingent consideration is established for business acquisitions where the Company has the obligation to transfer additional assets or equity interests to the former owners if specified future events occur or conditions are met. Contingent consideration is classified as a liability when the obligation requires settlement in cash or other assets and is classified as equity when the obligation requires settlement in the Company's own equity instruments. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with a corresponding adjustment to goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the measurement period (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date. All other subsequent changes in the fair value of contingent consideration classified as a liability are included in net loss in the period. Changes in the fair value of contingent consideration classified as equity are not recognized. During 2022, the Company settled contingent consideration for certain acquisitions that were completed in 2021. Refer to Note 14 – *Fair Value Measurements*, for further discussion of the contingent consideration.

For a given acquisition, the Company may identify certain pre-acquisition contingencies as of the acquisition date and may extend its review and evaluation of these pre-acquisition contingencies throughout the measurement period to obtain sufficient information to assess these contingencies as part of acquisition accounting, as applicable.

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date fair value amounts of the identifiable assets acquired, and the liabilities assumed.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Company reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period, or additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date that, if known, would have affected the amounts recognized at that time. Upon conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to net loss.

During 2021, the Company completed five acquisitions of branded manufacturers of CEA products, resulting in a significant expansion of its portfolio of proprietary branded products and manufacturing capabilities. The 2021 acquisitions included (i) Heavy 16, a manufacturer of plant nutrients and additives, in May 2021; (ii) House & Garden, a manufacturer of plant nutrients and additives, in June 2021; (iii) Aurora Innovations, a manufacturer of soil, grow media, plant nutrients and additives, in July 2021; (iv) Greenstar Plant Products, a manufacturer of plant nutrients and additives, in August 2021; and (v) Innovative Growers Equipment, a manufacturer of horticultural benches, racks and grow lights, in November 2021. The Company finalized the determination of its allocation of the purchase price relating to the acquisitions during 2022.

During the first quarter of 2022, the Company evaluated and adjusted the useful lives of certain intangible assets associated with entities that were acquired during 2021. In addition, the Company determined that the preliminary allocation of assets acquired related to indefinite lived trade names have a finite useful life because the expected usefulness of the trade names is limited. As a result of these adjustments to the provisional amounts, the Company recorded \$5,894 of additional amortization expense during the first quarter of 2022, which related to amortization expense that would have been recorded in the previous reporting period from the acquisition date through December 31, 2021. The intangible assets were assigned estimated useful lives as follows: (i) customer relationships: 7 to 12 years, (ii) technology, formulations and recipes: 8 to 12 years, (iii) computer software: 3 years, and (iv) trade names and trademarks: 15 to 20 years.

Restructuring

The Company began a restructuring plan (the "Restructuring Plan") **non-cash charges** during the three months ended **December 31, 2022** **March 31, 2023**, and undertook significant actions to streamline operations, reduce costs and improve efficiencies. The major initiatives of the first phase of the Restructuring Plan include (i) narrowing the Company's product and brand portfolio and (ii) the relocation and consolidation of certain manufacturing and distribution centers, including headcount reductions and reorganization to drive a solution based approach. The Company's strategic product consolidation entailed removing approximately one-third of all products and one-fifth of all brands relating to the Company's primary product portfolio, which excludes the garden center business in Canada.

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

During the three months ended September 30, 2023, the Company recorded a net restructuring benefit of \$243 for the first phase of the Restructuring Plan, primarily due to reversing an immaterial restructuring accrual. During the nine months ended September 30, 2023, the Company recorded net pre-tax charges of \$1,956 which were primarily related to the relocation and termination of certain facilities in Canada, partially offset by the aforementioned restructuring benefit. The Company incurred \$0 and \$744 of non-cash charges during the three and nine months ended September 30, 2023, respectively, relating to asset dispositions and write-downs. The Company recorded \$1,237 of restructuring related charges within Cost of goods sold and \$174 within Selling, general and administrative expenses on the consolidated statements of operations for the three months ended March 31, 2023. Total costs incurred relating to this first phase of the Restructuring Plan, since it commenced from its inception in the fourth quarter of 2022 are to its completion in 2023, were (i) \$6,398 relating primarily to inventory markdowns, and (ii) \$3,245 \$3,373 relating primarily to the relocation and termination of certain facilities in Canada.

As a result of the continued adverse market conditions, the Company is implementing implemented a second phase of the Restructuring Plan beginning in the third quarter of 2023, including U.S. manufacturing facility consolidations, in particular with respect to production of certain durable equipment products. The Company is reducing facility space and consolidating manufacturing operations to improve efficiency and reduce costs. During the three and nine months ended September 30, 2023 March 31, 2024, the Company recorded pre-tax restructuring charges of \$7,846 \$138 for the second phase, relating primarily to non-cash raw material inventory write-downs as cash charges associated with the Company plans to sell these assets and reduce storage space within certain consolidation of U.S. manufacturing facilities. These restructuring Of the \$138 recorded charges, are \$91 was recorded within Cost of goods sold on the condensed consolidated statements of operations, and are subject to significant estimate.

Including both phases of the Restructuring Plan, the Company recorded \$7,444 and \$9,401 of total restructuring charges within Cost of goods sold on the condensed consolidated statements of operations, for the three and nine months ended September 30, 2023, respectively. The Company while \$47 was recorded total charges for both phases of the Restructuring Plan of \$159 and \$401 within Selling, general and administrative ("SG&A") expenses on the condensed consolidated statements of operations for operations. Total costs incurred relating to this second phase of the three Restructuring Plan, from its commencement in the third quarter of 2023 through March 31, 2024, are (i) \$8,872 of non-cash charges relating primarily to inventory markdowns, and nine months ended September 30, 2023, respectively, (ii) \$451 of cash charges relating primarily to the consolidation of U.S. manufacturing facilities.

The following table presents tables present the activity in accrued expenses and other current liabilities for restructuring costs related to the first and second phases of the Restructuring Plan for the three and nine months ended September 30, 2023; March 31, 2023, and March 31, 2024, respectively:

	Three Months Ended September 30, 2023	
	Phase 1	Phase 2
Restructuring Accruals as of July 1, 2023	\$ 493	\$ —
(Reversal) Expense	(243)	150
Cash Payments	(225)	—
Restructuring Accruals as of September 30, 2023	\$ 25	\$ 150

	Three Months Ended March 31, 2023
Restructuring Accruals as of December 31, 2022	\$ 696
Expense	1,084
Cash Payments	(1,156)
Restructuring Accruals as of March 31, 2023	\$ 624

	Nine Months Ended September 30, 2023	
	Phase 1	Phase 2
Restructuring Accruals as of January 1, 2023	\$ 696	\$ —
Expense	1,213	150
Cash Payments	(1,884)	—
Restructuring Accruals as of September 30, 2023	\$ 25	\$ 150

	Three Months Ended March 31, 2024
Restructuring Accruals as of December 31, 2023	\$ 187
Expense	130
Cash Payments	(180)
Restructuring Accruals as of March 31, 2024	\$ 137

Refer to Item 2. Management's Discussion And Analysis Of Financial Condition And Results of Operations – Market Conditions for further explanation of the Restructuring Plan and estimates of additional costs that may be incurred. The amounts the Company will ultimately realize or disburse could differ from these estimates.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

Segment and entity-wide information

Segment information

The Company's chief operating decision maker is the chief executive officer ("CEO") who reviews financial information for the purposes of making operating decisions, assessing financial performance, and allocating resources. The business is organized as two operating segments, the United States and Canada, which meet the criteria for aggregation, and the Company has elected to present them as one reportable segment, which is the distribution and manufacture of CEA equipment and supplies. Aggregation is based on similarities which include the nature of its products, production or acquisition of inventory, customer base, fulfillment and distribution and economic characteristics.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

Since the Company operates as one reportable segment, all required segment financial information is found in the condensed consolidated financial statements and footnotes with entity-wide disclosures presented below.

Entity-wide information

Sales to external customers **Net sales** and property, plant and equipment, net and operating lease right-of-use assets in the United States and Canada, determined by the location of the subsidiaries, are shown below. Other foreign locations, which are immaterial, individually and in the aggregate, are included in the United States below.

		Three months ended September 30,		Nine months ended September 30,	
		2023	2022	2023	2022
Three months ended March 31,		Three months ended March 31,			
2024		2024		2023	
United States	United States	\$45,683	\$61,234	\$142,180	\$233,328
Canada	Canada	9,242	13,605	38,826	54,444
Intersegment eliminations	Intersegment eliminations	(757)	(684)	(1,609)	(4,732)
Total consolidated net sales	Total consolidated net sales	\$54,168	\$74,155	\$179,397	\$283,040
		September 30, 2023	December 31, 2022		
March 31, 2024		March 31, 2024		December 31, 2023	

United States	United States	\$ 71,538	\$ 80,380
Canada	Canada	33,236	36,020
Total property, plant and equipment, net and operating lease right-of-use assets	Total property, plant and equipment, net and operating lease right-of-use assets	\$ 104,774	\$116,400

All of the products sold by the Company are similar and classified as CEA equipment and supplies.

Fair value measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company has applied the framework for measuring fair value which requires a fair value hierarchy to be applied to all fair value measurements. All financial instruments recognized at fair value are classified into one of three levels in the fair value hierarchy as follows:

Level 1 — Valuation based on quoted prices (unadjusted) observed in active markets for identical assets or liabilities.

Level 2 — Valuation techniques based on inputs that are quoted prices of similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not in active markets; inputs other than quoted prices used in a valuation model that are observable for that instrument; and inputs that are derived from or, corroborated by, observable market data by correlation or other means.

Level 3 — Valuation techniques with significant unobservable market inputs.

The Company measures certain non-financial assets and liabilities, including long-lived assets and intangible assets and goodwill, at fair value on a nonrecurring basis. The fair value of contingent consideration was classified within level 3 of the fair value hierarchy. Refer to Note 14 – Fair Value Measurements, for further discussion of the contingent consideration.

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

Inventories

Inventories consist of finished goods, work-in-process, and raw materials used in manufacturing products. Inventories are stated at the lower of cost or net realizable value, principally determined by the first in, first out method of accounting. The Company maintains an allowance for excess and obsolete inventory. The estimate for excess and obsolete inventory is based upon assumptions about current and anticipated demand, customer preferences, business strategies, and market conditions. Management reviews these assumptions periodically to determine if any adjustments are needed to the allowance for excess and obsolete inventory. The establishment of an allowance for excess and obsolete inventory establishes a new cost basis in the inventory. Such allowance is not reduced until the product is sold or otherwise disposed. If inventory is sold, any related reserves would be reversed in the period of sale. During the year ended December 31, 2022 December 31, 2023, and the three and nine months ended September 30, 2023 March 31, 2024, the Company estimated inventory markdowns relating to restructuring charges based upon current and

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

anticipated demand, customer preferences, business strategies, and market conditions including management's actions with respect to inventory raw materials and products and brands being removed from the Company's portfolio. Hydrofarm's strategic product consolidation entailed removing approximately one-third of all products and one-fifth of all brands relating to the Company's primary product portfolio.

Note receivable and Investment

In 2019, the Company executed a note receivable secured by equipment to a third-party, the terms of which were amended and restated during the first quarter of 2021. The note receivable provided for interest and installment payments to the Company, and full maturity of the note in 2024. During the first quarter of 2022, the third-party defaulted on interest payments, and the Company measured an impairment on the note receivable based on the estimated fair value of the collateral. The Company recorded impairment losses of zero and \$2,636 during the three and nine months ended September 30, 2022, respectively, in Impairments on the condensed consolidated statements of operations. As of

December 31, 2022, the note receivable carrying value was \$475 and it was classified in Other assets on the condensed consolidated balance sheet. During the first quarter of 2023, the Company agreed to forgive the note receivable in exchange for interest in a third-party equity investment. The investment is recorded at an estimated cost basis of \$531, inclusive of capitalized transaction costs, which is reported within Other assets on the condensed consolidated balance sheet.

Revenue recognition

The Company follows Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") ASC 606 - Revenue from Contracts with Customers ("ASC 606") which requires that revenue recognized from contracts with customers be disaggregated into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The Company has determined that revenue is generated from one category, which is the distribution and manufacture of CEA equipment and supplies.

Revenue is recognized as control of promised goods is transferred to customers, which generally occurs upon receipt at customers' locations determined by the specific terms of the contract. Arrangements generally have a single performance obligation and revenue is reported net of variable consideration which includes applicable volume rebates, cash discounts and sales returns and allowances. Variable consideration is estimated and recorded at the time of sale.

The amount billed to customers for shipping and handling costs included in net sales was \$1,813 \$2,939 and \$7,099 \$2,568 during the three and nine months ended September 30, 2023 March 31, 2024, respectively, and \$3,103 and \$10,661 during the three and nine months ended September 30, 2022, 2023 respectively. Shipping and handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs included in cost of goods sold. The Company does not receive noncash consideration for the sale of goods. Contract consideration received from a customer prior to revenue recognition is recorded as a contract liability and is recognized as revenue when the Company satisfies the related performance obligation under the terms of the contract. The Company's contract liabilities, which consist primarily of customer deposits reported within deferred revenue in the condensed consolidated balance sheets, totaled \$3,564 \$2,841 and \$3,654 \$3,231 as of September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, respectively. There are no significant financing components, components and the majority of revenue is recognized within one year. Excluded from revenue are any taxes assessed by governmental authorities, including value-added and other sales-related taxes that are imposed on and concurrent with revenue-generating activities.

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

Income taxes

The income tax provision is calculated for an interim period by distinguishing between elements recognized in the income tax provision through applying an estimated annual effective tax rate to a measure of year-to-date operating results referred to as "ordinary income (or loss)," and discretely recognizing specific events referred to as "discrete items" as they occur. The income tax provision or benefit for each interim period is the difference between the year-to-date amount for the current period and the year-to-date amount for the prior period.

Recent accounting pronouncements

In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* (ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This ASU will be effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company considers is currently evaluating the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the FASB. There were no ASUs that were assessed and determined to be applicable or expected to have a material impact this ASU on the Company's condensed its consolidated financial statements.

3. GOODWILL AND INTANGIBLE ASSETS, NET

Goodwill

Primarily due In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to a sustained decline Income Tax Disclosures* (ASU 2023-09), which requires greater disaggregation of information in the Company's market value of common stock effective tax rate reconciliation, income taxes paid disaggregated by jurisdiction, and market conditions, the Company identified a triggering event requiring a test certain other amendments related to income tax disclosures. This guidance will be effective for impairment as of June 30, 2022 fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company completed is currently evaluating the impact of this ASU on its goodwill impairment testing and recorded an impairment charge of \$189,572 as the test determined that the carrying value of the U.S. and Canada reporting units was in excess of the fair value. The recognized impairment reduced the goodwill balance to zero as of June 30, 2022. The impairment was primarily due to a deterioration in customer demand in the United States and Canada caused by macroeconomic and industry conditions.

The Company determined the fair value of the U.S. and Canada reporting units based on an income approach, using the present value of future discounted cash flows, and based on a market approach. The fair values were reconciled to the market value of common stock of Hydrofarm to corroborate the estimates used in the interim test for impairment. Significant estimates used to determine fair value include the weighted average cost of capital, consolidated financial forecasts, and pricing multiples derived from publicly-traded companies that are comparable to the reporting units. Refer to Note 14 – statements, *Fair Value Measurements*, for further discussion of valuation inputs. The changes in goodwill are as follows:

	Goodwill
Balance at December 31, 2021	\$ 204,868
Acquisition - Innovative Growers Equipment - measurement period adjustments	(21,304)
Acquisition - Greenstar Plant Products - measurement period adjustments	7,000
Acquisition - all others - remeasurement adjustments and foreign currency translation adjustments, net	(992)
Impairments	(189,572)
Balance at September 30, 2022	\$ —

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

Intangible assets, net 3. INTANGIBLE ASSETS, NET

Intangible assets, net comprised the following:

		September 30, 2023			December 31, 2022						
		Gross			Gross						
		Carrying	Accumulated	Net Book	Carrying	Accumulated	Net Book				
		Amount	Amortization	Value	Amount	Amortization	Value				
		March 31, 2024			March 31, 2024			December 31, 2023			
		Gross Carrying				Gross Carrying	Accumulated	Net Book	Gross Carrying	Accumulated	Net Book
		Amount				Amount	Amortization	Value	Amount	Amortization	Value
Finite-lived intangible assets:	Finite-lived intangible assets:										
Computer software											
Computer software											
Computer software	Computer software	\$ 9,338	\$ (8,256)	\$ 1,082	\$ 9,408	\$ (7,976)	\$ 1,432				
Customer relationships	Customer relationships	99,808	(30,046)	69,762	99,933	(24,533)	75,400				
Technology, formulations and recipes	Technology, formulations and recipes	114,181	(22,679)	91,502	114,187	(15,344)	98,843				
Trade names and trademarks	Trade names and trademarks	131,491	(15,066)	116,425	131,410	(10,052)	121,358				
Other	Other	4,775	(4,357)	418	4,778	(4,246)	532				
Total finite-lived intangible assets, net	Total finite-lived intangible assets, net	359,593	(80,404)	279,189	359,716	(62,151)	297,565				
Indefinite-lived intangible asset:	Indefinite-lived intangible asset:										
Trade name	Trade name	2,801	—	2,801	2,801	—	2,801				
Trade name											
Trade name											

Total Intangible assets, net	Total Intangible assets, net	\$362,394	\$ (80,404)	\$281,990	\$362,517	\$ (62,151)	\$300,366
------------------------------------	------------------------------------	-----------	-------------	-----------	-----------	-------------	-----------

Amortization expense related to intangible assets was \$6,180 \$6,084 and \$18,272 \$6,045 for the three and nine months ended September 30, 2023 March 31, 2024, respectively. Amortization expense related to intangible assets was \$6,218 and \$27,209 for the three and nine months ended September 30, 2022, 2023, respectively. The following are the estimated useful lives and the weighted-average amortization period remaining as of September 30, 2023 March 31, 2024, for the major classes of finite-lived intangible assets:

	Useful lives	Weighted-average amortization period remaining
Computer software	3 to 5 years	2 years
Customer relationships	7 to 18 years	10 years
Technology, formulations and recipes	8 to 12 years	9 years
Trade names and trademarks	15 to 20 years	17 years

The estimated aggregate future amortization expense for intangible assets subject to amortization as of September 30, 2023 March 31, 2024, is summarized below:

	Estimated Future Amortization Expense
For the period of October 1, 2023 to December 31, 2023	\$ 6,136
Estimated Future Amortization Expense	Estimated Future Amortization Expense
For the period of April 1, 2024 to December 31, 2024	
Year ending December 31, 2024	24,489
2025	
2025	
2025	2025 24,271
2026	2026 24,011
2027	2027 23,820
Thereafter	176,462
2028	
2029 and thereafter	
Total	Total \$ 279,189

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

4. EARNINGS (LOSS) LOSS PER COMMON SHARE ("EPS")

Basic EPS loss per common share is computed using net income (loss) divided by the weighted-average number of common shares outstanding during each period, excluding unvested restricted stock units ("RSUs") and performance stock units ("PSUs").

Diluted EPS loss per common share represents net income (loss) divided by the weighted-average number of common shares outstanding during the period, including common stock equivalents. Common stock equivalents consist of shares subject to warrants and share-based awards with exercise prices less than the average market price of the Company's common stock for the period, to the extent their inclusion would be dilutive. Regarding RSUs subject to a market condition, before the end of the contingency period, the number of contingently issuable shares (i.e., RSUs) to be included in diluted EPS loss per common share would be based on the number of shares of common stock issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, assuming the result would be dilutive. Those contingently issuable shares would be included in the denominator of diluted EPS loss per common share as of the beginning of the period, or as of the grant date of the share-based payment, if later.

The following table presents basic and diluted EPS loss per common share for the three and nine months ended September 30, 2023 March 31, 2024 and 2022: 2023:

		Three months ended September 30,		Nine months ended September 30,	
		2023	2022	2023	2022
Three months ended March 31,		Three months ended March 31,			
2024		2024		2023	
Net loss	Net loss	\$ (19,884)	\$ (23,539)	\$ (49,598)	\$ (250,147)
Weighted-average shares of common stock outstanding	Weighted-average shares of common stock outstanding	45,607,195	45,089,286	45,429,139	44,907,355
Dilutive effect of warrants and share based compensation awards using the treasury stock method	Dilutive effect of warrants and share based compensation awards using the treasury stock method	—	—	—	—
Diluted weighted-average shares of common stock outstanding	Diluted weighted-average shares of common stock outstanding	45,607,195	45,089,286	45,429,139	44,907,355
Basic EPS		\$ (0.44)	\$ (0.52)	\$ (1.09)	\$ (5.57)
Diluted EPS		\$ (0.44)	\$ (0.52)	\$ (1.09)	\$ (5.57)
Basic loss per common share					
Diluted loss per common share					

The computation of the weighted-average shares of common stock outstanding for diluted EPS loss per common share excludes the following potential shares of common stock as their inclusion would have an anti-dilutive effect on diluted EPS: loss per common share:

		Three months ended September 30,		Nine months ended September 30,	
		2023	2022	2023	2022
Three months ended March 31,		Three months ended March 31,			
2024		2024		2023	
Shares subject to warrants outstanding	Shares subject to warrants outstanding	17,669	17,669	17,669	17,669

Shares subject to unvested performance and restricted stock units	Shares subject to unvested performance and restricted stock units	2,310,588	1,220,733	2,310,588	1,220,733
Shares subject to stock options outstanding	Shares subject to stock options outstanding	577,961	682,361	577,961	682,361

5. ACCOUNTS RECEIVABLE, NET, AND INVENTORIES

Accounts receivable, net comprised the following:

		September 30, 2023	December 31, 2022		
	March 31, 2024			March 31, 2024	December 31, 2023
Trade accounts receivable	Trade accounts receivable	\$ 17,331	\$ 18,204		
Allowance for doubtful accounts	Allowance for doubtful accounts	(1,344)	(1,556)		
Other receivables	Other receivables	1,083	579		
Total accounts receivable, net	Total accounts receivable, net	\$ 17,070	\$ 17,227		

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

The change in the allowance for doubtful accounts consisted of the following:

	Three months ended March 31,	
	2024	2023
Beginning balance	\$ (920)	\$ (1,556)
Changes in estimates	(124)	(108)
Write-offs	229	130
Collections/Other	31	370
Ending balance	\$ (784)	\$ (1,164)

Inventories comprised the following:

	September 30, 2023	December 31, 2022		
	March 31, 2024		March 31, 2024	December 31, 2023

Finished goods	Finished goods	\$ 61,378	\$ 83,134
Work-in-process	Work-in-process	3,731	5,403
Raw materials	Raw materials	25,102	38,558
Allowance for inventory obsolescence	Allowance for inventory obsolescence	(10,110)	(15,697)
Total inventories	Total inventories	\$ 80,101	\$111,398

Inventories are stated at the lower of cost or net realizable value, and the Company maintains an allowance for excess and obsolete inventory that is based upon assumptions about future demand and market conditions. The allowance for excess and obsolete inventory is subject to change from period to period based on a number of factors including sales of products, changes in estimates, and disposals.

6. LEASES

The Company leases its distribution centers and manufacturing facilities from third parties under various non-cancelable lease agreements expiring at various dates through 2038. Also, the Company leases some property, plant and equipment under finance leases. Certain leases contain escalation provisions and/or renewal options, giving the Company the right to extend the leases by up to 20 years. However, these options are generally not reflected in the calculation of the right-of-use assets and lease liabilities due to uncertainty surrounding the likelihood of renewal. The Company recognizes operating lease costs over the respective lease periods, including short-term and month-to-month leases. The Company incurred operating lease costs of \$2,897, \$2,750 and \$9,622, \$3,647 during the three and nine months ended September 30, 2023, March 31, 2024, respectively, and \$2,929 and \$8,548 during the three and nine months ended September 30, 2022, March 31, 2023, respectively. These costs are included primarily within SG&A in the condensed consolidated statements of operations.

The Company has operating subleases which have been accounted for by reference to the underlying asset subject to the lease, primarily as an offset to rent expense within SG&A. For the three and nine months ended September 30, 2023, March 31, 2024, and March 31, 2023, the Company recorded sublease income of \$323, \$738 and \$1,495, respectively. For the three and nine months ended September 30, 2022, the Company recorded sublease income of \$351 and \$900, \$642, respectively.

In January 2023, Gotham Properties LLC, an Oregon limited liability company and a subsidiary of the Company ("Seller"), consummated a Purchase and Sale Agreement with J & D Property, LLC, a Nevada limited liability company ("Purchaser") pursuant to which certain real property located in the City of Eugene, County of Lane, State of Oregon (the "Eugene Property") was sold to Purchaser for \$8,598 and then leased back by Seller (the "Sale-Leaseback Transaction"). The new lease has a term of 15 years with annual rent starting at \$731 and fixed increases to the final year when annual rent is \$964. The Company is accounting for the transaction as a failed sale-leaseback which requires retaining the asset associated with the property and recognizing a corresponding financial liability for the cash received. The Eugene Property serves as the manufacturing and processing site for certain of the Company's grow media and nutrient brands. The Company intends to reinvest the net cash proceeds into certain permitted investments, such as capital expenditures. Refer to Note 9 — Debt for further discussion. The foregoing description of the reinvestment provisions does not purport to be complete and is qualified in its entirety by reference to the provisions of the Term Loan.

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

Total right-of-use ("ROU") assets, finance lease assets, and lease liabilities were as follows:

	Balance Sheet Classification	September 30, 2023	December 31, 2022		Balance Sheet Classification	March 31, 2024	December 31, 2023
Lease assets	Lease assets			Operating lease assets			
				Operating lease assets			
Operating lease assets	Operating lease right-of-use assets	\$ 56,655	\$ 65,265				

Finance lease assets	Finance lease assets	Property, plant and equipment, net	9,595	2,005
Total lease assets	Total lease assets		\$ 66,250	\$ 67,270
Lease liabilities	Lease liabilities			
Lease liabilities				
Lease liabilities				
Current:	Current:			
Current:				
Current:				
Operating leases				
Operating leases				
Operating leases	Operating leases	Current portion of operating lease liabilities	\$ 8,505	\$ 9,099
Finance leases	Finance leases	Current portion of finance lease liabilities	974	704
Noncurrent:	Noncurrent:			
Operating leases	Operating leases	Long-term operating lease liabilities	49,843	56,299
Operating leases				
Operating leases				
Finance leases	Finance leases	Long-term finance lease liabilities	8,956	1,200
Total lease liabilities	Total lease liabilities		\$ 68,278	\$ 67,302

The aggregate future minimum lease payments under long-term non-cancelable operating and finance leases with **remaining** terms greater than one year as of **September 30, 2023** March 31, 2024, are as follows:

	Operating	Finance
For the period of October 1, 2023 to December 31, 2023	\$ 2,723	\$ 374
	Operating	Operating Finance
For the period of April 1, 2024 to December 31, 2024		
Year ending December 31,	Year ending December 31,	

Gross property, plant and equipment	Gross property, plant and equipment	67,743	66,055
Less: accumulated depreciation	Less: accumulated depreciation	(19,624)	(14,920)
Total property, plant and equipment, net	Total property, plant and equipment, net	\$ 48,119	\$ 51,135

Depreciation, depletion and amortization expense related to property, plant and equipment, net was \$1,728 \$1,801 and \$5,893 \$1,962 for the three and nine months ended September 30, 2023 March 31, 2024, respectively. Depreciation, depletion and amortization expense related to property, plant and equipment, net was \$2,221 and \$6,006 for the three and nine months ended September 30, 2022, 2023, respectively.

As of September 30, 2023 March 31, 2024, Land, Building and improvements, Computer equipment, and Machinery and equipment contain finance leases assets, recorded at cost of \$12,774, \$12,173, less accumulated depreciation of \$3,179, \$3,153. As of December 31, 2022 December 31, 2023, Land, Building and improvements, Computer equipment, and Machinery and equipment contains contain finance leases assets, recorded at cost of \$3,128, \$12,783, less accumulated depreciation of \$1,123, \$3,468.

The increase Company operates peat bogs in finance lease assets primarily relates Alberta, Canada. Under current provincial laws the Company is subject to certain asset retirement obligations ("AROs") and the remediation of the peat bog sites are under provincial oversight. The Company periodically evaluates expected remediation costs associated with the peat bog sites that it operates. When the Company concludes that it is probable that a liability has been incurred, a provision is made for management's estimate of the liability. As of March 31, 2024, and December 31, 2023, the Company had AROs of \$491 and \$759, respectively, recorded in Accrued expenses and other current liabilities on the condensed consolidated balance sheets. As of March 31, 2024, and December 31, 2023, the Company had AROs of \$4,382 and \$4,457, respectively, recorded in Other long-term liabilities on the condensed consolidated balance sheets. The ARO changes related to the Sale-Leaseback Transaction various components of accretion, and additional obligations incurred were not significant.

8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities comprised the following:

		September 30, 2023	December 31, 2022			March 31, 2024	December 31, 2023
Accrued compensation and benefits	Accrued compensation and benefits	\$ 2,403	\$ 2,522				
Interest accrual							
Freight, custom and duty accrual	Freight, custom and duty accrual	981	1,022				
Goods in transit accrual	Goods in transit accrual	841	1,172				
Income tax accrual	Income tax accrual	281	451				
Other accrued liabilities	Other accrued liabilities	3,517	8,041				
Total accrued expenses and other current liabilities	Total accrued expenses and other current liabilities	\$ 8,023	\$ 13,208				

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

9. DEBT

Debt is comprised of the following:

		September 30, 2023	December 31, 2022
Term loan - net of unamortized discount and deferred financing costs of \$4,481 and \$5,142 as of September 30, 2023, and December 31, 2022, respectively		\$118,332	\$118,608
	March 31, 2024	March 31, 2024	December 31, 2023
Term loan - net of unamortized discount and deferred financing costs of \$3,983 and \$4,259 as of March 31, 2024, and December 31, 2023, respectively			
Other	Other	132	160
Total debt	Total debt	\$118,464	\$118,768
Current portion of long-term debt	Current portion of long- term debt	\$ 1,295	\$ 1,307
Long-term debt - net of unamortized discount and deferred financing costs of \$4,481 and \$5,142 as of September 30, 2023, and December 31, 2022, respectively		117,169	117,461
Current portion of long-term debt			
Current portion of long-term debt			

Long-term debt - net of unamortized discount and deferred financing costs of \$3,983 and \$4,259 as of March 31, 2024, and December 31, 2023, respectively			
Total debt	Total debt	\$118,464	\$118,768

Term Loan

On October 25, 2021, the Company and certain of its direct and indirect subsidiaries (the "Obligors") entered into a Credit and Guaranty Agreement with JPMorgan Chase Bank, N.A., as administrative agent for the lenders, pursuant to which the Company borrowed a \$125,000 senior secured term loan ("Term Loan"). The Term Loan was amended by Amendment No. 1 to Credit and Guaranty Agreement ("Amendment No. 1") effective on June 27, 2023, to replace the LIBOR referenced rates with SOFR referenced rates. Pursuant to Amendment No. 1, any Term Loan that constitutes a Eurodollar Rate Loan that is outstanding as of the Amendment No. 1 closing date shall continue until the end of the applicable interest period for such Eurodollar Rate Loan and the provisions of the Term Loan applicable thereto shall continue and remain in effect (notwithstanding the occurrence of the Amendment No. 1 closing date) until the end of the applicable interest period for such Eurodollar Rate Loan, after which such provisions shall have no further force or effect. Such Eurodollar Rate Loan shall subsequently either be an ABR Loan or a Term Benchmark Loan. The ABR Loans shall bear interest at the Alternate Base Rate (with a 2.0% floor) plus 4.50%, and Term Benchmark Loans shall bear interest at the Adjusted Term SOFR Rate (with a 1.0% floor), plus 5.50%. The ABR Loan and Term Benchmark Loan credit spreads of 4.50% and 5.50%, respectively, within the Amendment No. 1 have not changed from the credit spreads in the original Term Loan. Legal fees associated with Amendment No. 1 were not material, and were included in Other income, net, on the Condensed Consolidated Statements of Operations during the **three and nine months year ended September 30, 2023** **December 31, 2023**. The foregoing description of Amendment No. 1 does not purport to be complete and is qualified in its entirety by reference to the provisions of Amendment No. 1, included as Exhibit **10.2 10.8** to **this Form 10-Q, the 2023 Annual Report**. Capitalized terms referenced above are defined in the Term Loan.

The Term Loan **is was** subject to a call premium of 1% if called prior to October 25, 2023, and 0% thereafter, and matures on October 25, 2028 ("Maturity Date"). Deferred financing costs are being amortized to interest expense over the term of the loan. For the three months ended **September 30, 2023** **March 31, 2024**, the effective interest rate was **11.82%** **12.03%** and interest expense was **\$3,667**, **\$3,652**, which includes amortization of deferred financing costs and discount of **\$223**. **For the nine months ended September 30, 2023**, the effective interest rate was 11.42% and interest expense was \$10,543, which includes amortization of deferred financing costs and discount of **\$661**. **\$220**.

The principal amounts of the Term Loan are required to be repaid in consecutive quarterly installments in amounts equal to 0.25% of the original principal amount of the Term Loan, on the last day of each fiscal quarter commencing March 31, 2022, with the balance of the Term Loan payable on the Maturity Date. The Company is also required to make mandatory prepayments in the event of (i) achieving certain excess cash flow criteria, including the achievement and maintenance of a specific leverage ratio, (ii) **selling assets certain asset sales** that are collateral, or (iii) upon the issuance, offering, or placement of new debt obligations. As described in Note 6 – *Leases*, the Company **intends to reinvest the received** net cash proceeds **received** in January 2023 from the Sale-Leaseback Transaction **and is subject to a provision whereby such net cash proceeds can be reinvested** into certain **permitted** investments, such as capital expenditures. This provision of the Term Loan includes (i) cash investments made within a one-year period from the Sale Leaseback Transaction, and **includes (ii)** investments which are contractually committed within one-year **of the Sale Leaseback Transaction** and paid within 180 days after entering into such contractual commitment. **If applicable, the** **The** amount of any net cash proceeds which are not reinvested would require the Company to make **an offer to prepay the corresponding amount on the Term Loan in 2024**. **In accordance with this provision, the Company classified \$1,665 as current debt as of December 31, 2023, and prepaid the Term Loan in this amount in the first quarter of 2024. In addition, the Company had \$2,187 of contractual commitments**

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

pursuant to this provision as of December 31, 2023. Should any of the \$2,187 balance not be paid within 180 days of the contractual commitment dates, the Company will be required to make an additional offer to prepay the corresponding amount on the Term Loan in 2024. amount. The foregoing description of the reinvestment provision does not purport to be complete and is qualified in its entirety by reference to the provisions of the Term Loan.

There were no such mandatory prepayments made since inception of the Term Loan. As of September 30, 2023 **March 31, 2024**, and **December 31, 2022** **December 31, 2023**, the outstanding principal balance on the Term Loan was **\$122,813** **\$120,526** and **\$123,750**, **\$122,500**, respectively.

The Term Loan requires the Company to maintain certain reporting requirements, affirmative covenants, and negative covenants, and the Company was in compliance with all requirements as of **September 30, 2023** **March 31, 2024**. The Term Loan is secured by a first lien on the non-working capital assets of the Company and a second lien on the working capital assets of the Company.

Revolving Credit Facility

On March 29, 2021, the Obligors entered into a Senior Secured Revolving Credit Facility (the "Revolving Credit Facility") with JPMorgan Chase Bank, N.A., as administrative agent, issuing bank and swingline lender, and the lenders from time to time party thereto. The Revolving Credit Facility is due on June 30, 2026, or any earlier date on which the revolving commitments are reduced to zero.

The Revolving Credit Facility originally had a borrowing limit of \$50,000. On August 31, 2021, the Obligors entered into an amendment (the "First Amendment") to increase their original borrowing limit to \$100,000. In connection with the First Amendment, the Company's previously acquired subsidiaries became party to the Revolving Credit Facility as either borrowers or as guarantors. On October 25, 2021, the Company and its subsidiaries entered into a second amendment (the "Second Amendment"), with JPMorgan Chase Bank, N.A., pursuant to which the parties consented to the Term Loan described above, and made certain conforming changes to comport with the Term Loan provisions. The Revolving Credit Facility was further amended by a third amendment and joinder dated August 23, 2022 (the "Third Amendment"), pursuant to which several previously acquired subsidiaries became parties to the Revolving Credit Facility and granted liens on their assets. On December 22, 2022, the Company entered into a fourth amendment (the "Fourth Amendment") pursuant to which a sale-leaseback transaction was permitted, and certain other changes were made, including a reduction of the maximum commitment amount under the Revolving Credit Facility from \$100,000 to \$75,000 and transitioning the LIBOR based rates to SOFR based rates. On March 31, 2023, the Company and certain of its subsidiaries entered into an amendment (the "Fifth Amendment") pursuant to which the maturity date was extended to June 30, 2026, the maximum commitment amount under the Revolving Credit Facility was reduced to \$55,000, and the interest rate on borrowings was revised to various spreads, based on the Company's fixed charge coverage ratio.

The unamortized debt discount and deferred financing costs were \$573 \$484 and \$538 as of September 30, 2023 March 31, 2024, and December 31, 2023, respectively, and are included in other assets in the condensed consolidated balance sheets. Debt discount and deferred financing costs are being amortized to interest expense over the term of the Revolving Credit Facility.

The Revolving Credit Facility is an asset-based facility that is secured by a first lien on the working capital assets of the Company and a second lien on the non-working capital assets of the Company (including most of the Company's subsidiaries). The borrowing base is based on a detailed monthly calculation of the sum of (a) a percentage of the Eligible Accounts at such time, plus (b) the lesser of (i) a percentage of the Eligible Inventory, at such time, valued at the lower of cost or market value, determined on a first-in-first-out basis, and (ii) the product of a percentage multiplied by the Net Orderly Liquidation Value percentage identified in the most recent inventory appraisal ordered by the Administrative Agent multiplied by the Eligible Inventory, valued at the lower of cost or market value, determined on a first-in-first-out basis, minus (c) Reserves (each of the defined terms above, as defined in the Revolving Credit Facility documents).

The Company is required to maintain certain reporting requirements, affirmative covenants and negative covenants, pursuant to terms outlined in the agreement. Additionally, if the Company's Excess Availability (as defined in the Revolving Credit Facility documents) is less than an amount equal to 10% of the Aggregate Revolving Commitment (currently \$55,000), the Company will be required to maintain a minimum fixed charge coverage ratio of 1.1x on a rolling twelve-month basis until the Excess Availability is more than 10% of the Aggregate Revolving Commitment for thirty consecutive days. In order to consummate permitted acquisitions or to make restricted payments, the Company would be required to comply with a higher fixed charge coverage ratio of 1.15x, but no such acquisitions or payments are currently contemplated. As of September 30, 2023, the Company is in compliance with the covenants contained in the Revolving Credit Facility.

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

fixed charge coverage ratio of 1.15x, but no such acquisitions or payments are currently contemplated. As of March 31, 2024, the Company is in compliance with the covenants contained in the Revolving Credit Facility.

The Revolving Credit Facility provides for various interest rate options including the Adjusted Term SOFR Rate, the Adjusted REVSOFR30 Rate, the CB Floating Rate, the Adjusted Daily Simple SOFR, the CBFR, the Canadian Prime Rate, or the CDOR Rate. The rates that use SOFR as the reference rate (Adjusted Term SOFR Rate, the Adjusted REVSOFR30 Rate, the Adjusted Daily Simple SOFR and the CBFR rate) use the Term SOFR Rate plus 1.95%. Each rate has a 0.0% floor. A fee of 0.40% per annum is charged for available but unused borrowings.

As of September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, the Company had zero borrowed under the facility. As of September 30, 2023 March 31, 2024, the Company would be able to borrow approximately \$28 \$25 million under the Revolving Credit Facility, before the Company would be required to comply with the minimum fixed charge coverage ratio of 1.1x.

Other Debt

Other debt of \$132 \$125 and \$160 as of September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, respectively, was primarily comprised of a foreign subsidiary's other debt which constitutes an immaterial revolving line of credit and mortgage.

Aggregate future principal payments

As of September 30, 2023 March 31, 2024, the aggregate future principal payments under long-term debt are as follows:

Debt	
For the period of	
October 1, 2023 to	
December 31, 2023	\$ 344

Debt

Debt

For the period of April 1, 2024 to December 31, 2024		
Year ending December 31,	Year ending December 31,	
2024		1,268
2025		
2025		
2025	2025	1,269
2026	2026	1,269
2027	2027	1,269
2028	2028	117,526
2029 and thereafter		
Total	Total	\$ 122,945

10. STOCKHOLDERS' EQUITY

Common stock

Each holder of common stock is entitled to one vote for each share of common stock. Common stockholders have no pre-emptive rights to acquire additional shares of common stock or other securities. The common stock is not subject to redemption rights and carries no subscription or conversion rights. In the event of liquidation, the stockholders are entitled to share in corporate assets on a pro rata basis after the Company satisfies all liabilities and after provision is made for any class of capital stock having preference over the common stock. Subject to corporate regulations and preferences to preferred stock, if any, dividends are at the discretion of the Board of Directors. As of September 30, 2023 March 31, 2024, there were 45,688,695 45,977,935 shares outstanding and 300,000,000 shares authorized.

Warrants

On July 19, 2021, the Company completed the redemption ("Redemption") of certain of its outstanding warrants (the "Investor Warrants") that were issued in connection with a private placement of units (the "private placement"), each consisting of a share of common stock and a warrant to purchase an additional one-half (1/2) shares of common stock. In connection with the private placement, the Company agreed to engage the placement agent (the "Placement Agent") as the Company's warrant solicitation agent in the event the Investor Warrants were called for Redemption. The Company agreed to pay a warrant solicitation fee to the Placement Agent equal to five percent of the amount of net cash proceeds solicited by the Placement Agent upon the exercise of certain Investor Warrants following such call for Redemption. As of September 30, 2023, and December 31, 2022, respectively, there were no Investor Warrants outstanding. In connection with the private placement, the Placement Agent was issued warrants (the "placement agent warrants") which will expire on December 14, 2023.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

Agent upon the exercise of certain Investor Warrants following such call for Redemption. As of September 30, 2023 March 31, 2024, and December 31, 2023, respectively, there were no Investor Warrants outstanding. In connection with the following table summarizes private placement, the Placement Agent was issued warrants (the "placement agent warrants") which expired on December 14, 2023. As of March 31, 2024, and December 31, 2023, there were no outstanding placement agent warrants:

	Number of Warrants	Exercise Price
Placement agent warrants	11,662	\$ 8.43
Placement agent warrants	6,007	\$ 16.86
Total	17,669	\$ 11.30

As of December 31, 2022, the following table summarizes the outstanding placement agent warrants:

	Number of Warrants	Exercise Price
Placement agent warrants	11,662	\$ 8.43

Placement agent warrants	6,007	\$	16.86
Total	17,669	\$	11.30

warrants.

11. STOCK-BASED COMPENSATION

Stock-based compensation plan overview

The Company maintains three equity incentive plans: the 2018 Equity Incentive Plan ("2018 Plan"), the 2019 Employee, Director and Consultant Equity Incentive Plan ("2019 Plan") and the 2020 Employee, Director, and Consultant Equity Incentive Plan ("2020 Plan" and collectively, "Incentive Plans"). The 2020 Plan serves as the successor to the 2019 Plan and 2018 Plan and provides for the issuance of incentive stock options ("ISOs"), stock grants and stock-based awards to employees, directors, and consultants of the Company. No further awards will be issued under the 2018 Plan and 2019 Plan. As of September 30, 2023 March 31, 2024, a total of 1,427,455 4,065,385 shares are were available for grant under the 2020 Plan.

The Incentive Plans are administered by the Company's Board of Directors. Notwithstanding the foregoing, the Board of Directors may delegate concurrent responsibility for administering each plan, including with respect to designated classes of persons eligible to receive an award under each plan, to a committee or committees (which term shall include subcommittees) consisting of one or more members of the Board of Directors (collectively, the "Plan Administrator"), subject to such limitations as the Board of Directors deems appropriate.

In November 2020, the Board of Directors and stockholders approved the 2020 Plan and reserved an aggregate of 2,284,053 shares of common stock for issuance under the 2020 Plan. Pursuant to the 2020 Plan, the number of shares available for issuance under the 2020 Plan may be increased on January 1 of each year, beginning on January 1, 2021, and ending on January 2, 2030, in an amount equal to the lesser of (i) 4% of the outstanding shares of the Company's common stock on such date or (ii) such number of shares determined by the Plan Administrator.

The 2020 Plan provides for the grant of ISOs, nonqualified stock options, stock grants, and stock-based awards that are based in whole or in part by reference to the Company's common stock.

- The Plan Administrator may grant options designated as incentive stock options or nonqualified stock options. Options shall be granted with an exercise price per share not less than 100% of the fair market value of the common stock on the grant date, subject to certain limitations and exceptions as described in the plan agreements. Generally, the maximum term of an option shall be 10 years from the grant date. The Plan Administrator shall establish and set forth in each instrument that evidences an option the time at which, or the installments in which, the option shall vest and become exercisable.
- The Plan Administrator may grant stock grants and stock-based awards, including securities convertible into shares, stock appreciation rights, phantom stock awards or stock units on such terms and conditions which may be based on continuous service with the Company or related company or the achievement of any performance goals, as the Plan

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(dollars in thousands, except share and per share amounts)

Administrator shall determine in its sole discretion, which terms, conditions and restrictions shall be set forth in the instrument evidencing the award.

Restricted Stock Unit ("RSU") Activity

RSUs granted to certain executives, employees and members of the Board of Directors expire 10 years after the grant date. The awards generally have a time-based vesting requirement (based on continuous employment). Upon vesting, the RSUs convert into shares of the Company's common stock. The stock-based compensation expense related to service-based awards is recorded over the requisite service period. During the first quarter of 2023, the Company granted RSU awards that are expected to vest with two equal vesting tranches, one of which are scheduled to occur vested on October 31, 2023, and the second of which is scheduled to vest on October 31, 2024. During the second quarter of 2023, the Company granted RSU awards to members of the Board of Directors that are expected to vest on the one year anniversary of the grant date. During the three months ended September 30, 2023, the Company granted RSU awards that are expected to vest with three equal vesting tranches, annually on the anniversary of the grant date.

The award granted to a former member of the Board (the "former Board member") in July 2020, and modified in November 2020, contained a market-based vesting condition based on the traded value of shares of the Company's common stock following the Company's initial public offering ("IPO") over a specific time frame. For this award, the market condition was factored into its fair value. The fair value of the award, at the modification date, was \$3,180, all of which was recorded as stock-based compensation expense upon the IPO. In July 2021, the market-based vesting condition for this award was satisfied and 148,315 RSUs of the former Board member vested. The remaining 111,236 unvested RSUs met the time-based vesting conditions during the year ended December 31, 2022, and vested at that time. No additional awards with market-based conditions have been granted.

The following table summarizes the activity related to the Company's RSUs for the nine months ended September 30, 2023. For purposes of this table, vested RSUs represent the shares for which the service condition had been fulfilled during the nine months ended September 30, 2023:

	Number of RSUs	Weighted average grant date fair value

Balance, December 31, 2022	992,633	\$	8.57
Granted	1,091,726	\$	1.19
Vested	(639,118)	\$	7.54
Forfeited	(62,723)	\$	11.05
Balance, September 30, 2023	1,382,518	\$	3.11

As of September 30, 2023, total unamortized stock-based compensation cost related to unvested RSUs was \$3,022 and the weighted-average period over which the compensation is expected to be recognized is 1.29 years. For the three and nine months ended September 30, 2023, the Company recognized \$1,073 and \$3,501, respectively, of total stock-based compensation expense for RSUs. As of September 30, 2023, there were 6,357 RSUs which had previously vested, but were not yet issued due to the recipients' elections to defer the awards.

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

The following table summarizes the activity related to the Company's RSUs for the three months ended March 31, 2024. For purposes of this table, vested RSUs represent the shares for which the service condition had been fulfilled during the three months ended March 31, 2024:

	Number of RSUs	Weighted average grant date fair value
Balance, December 31, 2023	1,242,210	\$ 3.06
Vested	(112,720)	\$ 13.75
Balance, March 31, 2024	1,129,490	\$ 1.99

As of March 31, 2024, total unamortized stock-based compensation cost related to unvested RSUs was \$1,269 and the weighted-average period over which the compensation is expected to be recognized is less than one year. For the three months ended March 31, 2024, the Company recognized \$752 of total stock-based compensation expense for RSUs. As of March 31, 2024, there were 6,357 RSUs which had previously vested, but were not yet issued due to the recipients' elections to defer the awards.

Performance Stock Unit ("PSU") Activity

During the first quarter of 2023, the Company granted PSU awards that are subject to a one-year vesting requirement (based on continuous employment) and contain performance conditions based on certain performance metrics. The following table summarizes the activity related to the Company's PSUs for the **nine three** months ended **September 30, 2023** March 31, 2024:

	Number of PSUs	Weighted average grant date fair value
Balance, December 31, 2022	96,246	\$ 15.74
Granted	1,141,543	\$ 1.77
Vested	(25,894)	\$ 15.74
Forfeited	(283,825)	\$ 5.23
Balance, September 30, 2023	928,070	\$ 1.77

	Number of PSUs	Weighted average grant date fair value
Balance, December 31, 2023	921,182	\$ 1.77
Vested	(180,298)	\$ 1.77
Forfeited	(740,884)	\$ 1.77
Balance, March 31, 2024	—	\$ —

During the **nine three** months ended **September 30, 2023** March 31, 2024, the PSU forfeitures were due to employee terminations and performance conditions that were not satisfied, while PSU vests were from awards granted in prior periods. The majority of the PSUs outstanding as of December 31, 2023 were forfeited in the three months ended March 31, 2024, as a result of not meeting certain performance conditions. As of **September 30, 2023** March 31, 2024, **total** there was no unamortized stock-based compensation

cost related to or unvested PSUs was \$231 and the weighted-average period over which the compensation is expected to be recognized is less than one-year, outstanding. For the three and nine months ended September 30, 2023 March 31, 2024, the Company recognized \$(110) and \$306, respectively, \$72 of total stock-based compensation (benefit) expense for PSUs. The Company issued 1,372,188 additional PSUs in April 2024, which are scheduled to vest in April 2025, assuming certain performance metrics are achieved.

Stock Options

The vesting of stock options is subject to certain change in control provisions as provided in the incentive plan agreements and options may be exercised up to 10 years from the date of issuance.

There were no stock options granted or exercised during the nine months ended September 30, 2023. The following table summarizes the stock option activity for the nine months ended September 30, 2023:

	Number	Weighted average exercise price	Weighted average grant date fair value	Weighted average remaining contractual term (years)
Outstanding as of December 31, 2022	670,026	\$ 9.50	\$ 2.05	5.25
Cancelled	(87,749)	\$ 8.80	\$ 1.69	
Forfeited	(4,316)	\$ 12.85	\$ 7.85	
Outstanding as of September 30, 2023	577,961	\$ 9.58	\$ 2.15	3.81
Options exercisable as of September 30, 2023	543,551	\$ 9.23	\$ 1.61	3.63
Vested and expected to vest as of September 30, 2023	577,961	\$ 9.58	\$ 2.15	3.81

The following table summarizes the unvested stock option activity for the nine months ended September 30, 2023:

	Number	Weighted average grant date fair value
Unvested as of December 31, 2022	70,587	\$ 7.02
Vested	(31,861)	\$ 4.38
Forfeited	(4,316)	\$ 7.85
Unvested as of September 30, 2023	34,410	\$ 10.62

[TABLE OF CONTENTS](#)

Hydrofarm Holdings Group, Inc. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (dollars in thousands, except share and per share amounts)

There were no stock options granted or exercised during the three months ended March 31, 2024. The following table summarizes the stock option activity for the three months ended March 31, 2024:

	Number	Weighted average exercise price	Weighted average grant date fair value	Weighted average remaining contractual term (years)
Outstanding as of December 31, 2023	571,359	\$ 9.47	\$ 2.01	3.69
Cancelled	(127,576)	\$ 8.44	\$ 0.92	
Forfeited	(39)	\$ 11.06	\$ 9.89	
Outstanding as of March 31, 2024	443,744	\$ 9.76	\$ 2.33	4.44
Options exercisable as of March 31, 2024	427,922	\$ 9.38	\$ 1.95	4.35
Vested and expected to vest as of March 31, 2024	443,744	\$ 9.76	\$ 2.33	4.44

The following table summarizes the unvested stock option activity for the three months ended March 31, 2024:

	Number	Weighted average grant date fair value
Unvested as of December 31, 2023	16,674	\$ 12.15

Vested	(813)	\$	3.85
Forfeited	(39)	\$	9.89
Unvested as of March 31, 2024	15,822	\$	12.59

As of September 30, 2023 March 31, 2024, total compensation cost related to unvested awards options not yet recognized was \$209 \$84 and the weighted-average period over which the compensation is expected to be recognized is 1.06 years, less than one-year. For the three and nine months ended September 30, 2023 March 31, 2024, the Company recognized \$59 and \$214, respectively, \$29 of total stock-based compensation expense for stock options.

12. INCOME TAXES

The Company recorded income tax expense of \$89 \$196 for the three months ended September 30, 2023 March 31, 2024, representing an effective tax rate of (0.4) (1.6)%. The Company recorded an income tax benefit of \$82 for the nine months ended September 30, 2023, representing an effective income tax rate of 0.2%. The Company's effective tax rate for the nine three months ended September 30, 2023 March 31, 2024, differs from the federal statutory rate of 21% primarily due to the Company maintaining a full valuation allowance against its net deferred tax assets in the U.S. and most foreign jurisdictions. The income tax expense and benefit for the three and nine months ended September 30, 2023 March 31, 2024, respectively, was primarily due to minor U.S. state taxes and foreign tax items taxes in certain jurisdictions.

The Company recorded income tax expense of \$759 \$147 for the three months ended September 30, 2022 March 31, 2023, representing an effective tax rate of (3.3) (0.9)%. The Company recorded an income tax benefit of \$11,671 for the nine months ended September 30, 2022, representing an effective income tax rate of 4.5%. The Company's effective tax rate for the nine three months ended September 30, 2022 March 31, 2023, differs from the federal statutory rate of 21% primarily due to the impairment of goodwill for certain 2021 acquisitions which was not deductible for United States tax purposes, increases in the Company's Company maintaining a full valuation allowance on U.S. against its net deferred tax assets in the U.S. and the establishment of a valuation allowance most foreign jurisdictions. The tax expense for Canadian deferred tax assets. As described in Note 3 – Goodwill and Intangible Assets, Net, during the three months ended June 30, 2022 March 31, 2023, the Company fully impaired the goodwill associated with all 2021 acquisitions. For the nine months ended September 30, 2022, the Company recorded discrete income was primarily due to foreign tax benefits of \$12,058 relating primarily to measurement period adjustments associated with 2021 acquisitions, and certain tax benefits related to goodwill impairment.expense.

13. COMMITMENTS AND CONTINGENCIES

Purchase commitments

From time to time in the normal course of business, the Company will enter into agreements with suppliers which provide favorable pricing in return for a commitment to purchase minimum amounts of inventory over a defined time period.

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

Contingencies

In the normal course of business, certain claims have been brought against the Company and, where applicable, its suppliers. While there is inherent difficulty in predicting the outcome of such matters, management has vigorously contested the validity of these claims. Based on available information, management believes the claims are without merit and does not expect that the outcome of any matters, individually or in the aggregate, would have a material adverse effect on the consolidated financial positions, position, results of operations, cash flows or future earnings, earnings of the Company.

14. FAIR VALUE MEASUREMENTS

Recurring and Nonrecurring

Contingent consideration, as described under the heading Business combinations in Note 2 – Basis of Presentation and Significant Accounting Policies, was measured at estimated The Company did not have any assets or liabilities that were remeasured to fair value on a recurring or nonrecurring basis and based on Level 3 fair value measurements. The fair value of the contingent consideration for the Heavy 16 and Aurora Innovations acquisitions was \$200 and \$16,834, respectively, as of December 31, 2021. There was no change in the fair value of the contingent consideration for the Heavy 16 acquisition during fiscal year 2022, and it was paid in April 2022. The change in the fair value of contingent consideration for the Aurora Innovations acquisition was a benefit of \$1,560, during the six months ended June 30, 2022, and was recognized in SG&A on the condensed consolidated statements of operations during that period. The value of the contingent consideration was \$15,274 as of June 30, 2022, and was subsequently paid in July 2022. As of September 30, 2023, periods presented.

TABLE OF CONTENTS

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

and December 31, 2022, the Company had no remaining unsettled contingent consideration relating to the Company's five acquisitions from 2021.

Nonrecurring

Nonrecurring fair value measurements include the Company's goodwill impairment recognized during the three and six months ended June 30, 2022, as determined based on unobservable Level 3 inputs. Refer to Note 3 – *Goodwill and Intangible Assets, Net*, for further discussion.

The note receivable, as described in Note 2 – *Basis of Presentation and Significant Accounting Policies*, was measured at fair value on a nonrecurring basis. During the nine months ended September 30, 2022, the Company measured an impairment on the note receivable based on the estimated fair value of the collateral, which was considered a Level 3 fair value measurement. The carrying value of the note receivable was \$3,111 as of December 31, 2021. The Company recorded an impairment loss of zero and \$2,636 during the three and nine months ended September 30, 2022, recognized in Impairments on the condensed consolidated statements of operations. The carrying value of the note receivable was \$475 as of December 31, 2022. As of December 31, 2022, the note receivable was included in other assets on the condensed consolidated balance sheet.

Other Fair Value Measurements

The following table summarizes the fair value of the Company's assets and liabilities which are provided for disclosure purposes:

		September 30, 2023		December 31, 2022							
		Fair Value									
		Hierarchy Level	Carrying Amount	Estimated Fair Value	Carrying Amount	Estimated Fair Value					
		March 31, 2024						March 31, 2024		December 31, 2023	
		Fair Value Hierarchy Level				Fair Value Hierarchy Level		Carrying Amount	Estimated Fair Value	Carrying Amount	Estimated Fair Value
Assets	Assets										
Cash and equivalents	cash equivalents										
Cash and equivalents	cash equivalents										
Cash and equivalents	Cash and cash equivalents	Level 1	32,457	32,457	21,291	21,291	Level 1	24,152		30,312	
Liabilities	Liabilities										
Liabilities	Liabilities										
Liabilities	Liabilities										
Finance leases	Finance leases										
Finance leases	Finance leases										
Finance leases	Finance leases	Level 3	9,930	9,930	1,904	1,904	Level 3	9,427		9,688	
Term Loan	Term Loan	Level 2	122,813	98,250	123,750	105,188	Term Loan 2	120,526		97,024	
										122,500	98,000

Hydrofarm Holdings Group, Inc.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(dollars in thousands, except share and per share amounts)

The Company will continue to sell its proprietary branded durable products. In connection with the transaction, the Company is entering into an exclusive supply agreement with the Buyer to provide for contract manufacturing, yielding a more efficient cost model going forward. JPMorgan Chase Bank, N.A., as administrative agent to the Company's Revolving Credit Facility, granted a consent to permit the Asset Sale. In accordance with the Company's Term Loan, the net proceeds from the Asset Sale transaction are required to be reinvested into certain permitted investments, such as capital expenditures, or offered to prepay Term Loan principal.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our results of operations and financial condition. You should read this analysis in conjunction with our audited and unaudited consolidated financial statements and the notes contained elsewhere in this Quarterly Report on Form 10-Q and our 2022 2023 Annual Report. This discussion and analysis contains statements of a forward-looking nature relating to future events or our future financial performance. These statements are only predictions, and actual Actual events or results may differ materially, materially from forward-looking statements. In evaluating such statements, you should carefully consider the various factors identified in this Quarterly Report on Form 10-Q, which could cause actual results to differ materially from those expressed in, or implied by, any forward-looking statements, including those set forth in "Risk Factors" in our 2022 2023 Annual Report. See "Special Note Regarding Forward-Looking Statements."

Company Overview

We are a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture ("CEA"), including grow lights, climate control solutions, growing media and nutrients, as well as a broad portfolio of innovative and proprietary branded products. We primarily serve the U.S. and Canadian markets, and believe we are one of the leading competitors companies in these markets in an otherwise highly fragmented industry. For over 40 years, we have helped growers make growing easier and more productive. Our mission is to empower growers, farmers and cultivators with products that enable greater quality, efficiency, consistency, and speed in their grow projects.

Hydroponics is the farming of plants using soilless growing media and often artificial lighting in a controlled indoor or greenhouse environment. Hydroponics is the primary category of CEA and we use the terms CEA and hydroponics interchangeably. Our products are used to grow, farm, and cultivate cannabis, flowers, fruits, plants, vegetables, grains and herbs in controlled environment settings that allow end users to control key farming variables including temperature, humidity, CO₂, light intensity spectrum, nutrient concentration and pH. Through CEA, growers are able to be more efficient with physical space, water and resources, while enjoying year-round and more rapid grow cycles as well as more predictable and abundant grow yields, when compared to other traditional growing methods.

We reach commercial farmers and consumers through a broad and diversified network of over 2,000 wholesale customer accounts, who we connect with primarily through our proprietary online ordering platform. Our products are distributed across the United States and Canada through a diversified range of retailers of commercial and home gardening equipment and supplies. Our customers include specialty hydroponic retailers, commercial resellers and greenhouse builders, garden centers, hardware stores, and e-commerce retailers. Specialty hydroponic retailers can provide growers with specialized merchandise assortments and knowledgeable staff.

Market Conditions

We have experienced adverse financial results which we believe is primarily a result of an agricultural oversupply impacting our market. An agricultural oversupply has impacted our industry, driving cannabis wholesale prices down and resulting in a decrease in indoor and outdoor cultivation in the markets where we operate. The extent to which these market conditions will continue to negatively impact our business and results of operations is uncertain and difficult to predict at this time. We believe COVID-19 may have provided a positive demand impact for the Company in 2020 and 2021 from shelter-in-place orders in the United States, a possible negative supply chain impact from workforce disruption at international and domestic suppliers, and a possible negative growth rate impact in 2022 and 2023 due to agricultural oversupply initiated during the height of COVID-related shelter-in-place orders in 2020 and 2021.

In connection with our previously disclosed evaluation of our facility footprint and product and brand portfolio, we initiated a restructuring plan (the "Restructuring Plan") during the three months ended December 31, 2022. 2022. In connection with the first phase of our Restructuring Plan, we have undertaken significant actions to streamline our operations, reduce costs and improve efficiencies during the industry recession. Our major initiatives included (i) narrowing our product and brand portfolio, including removing approximately one-third of all products and one-fifth of all brands relating to our primary product portfolio, which excluded our garden center business in Canada, and (ii) relocating and consolidating certain manufacturing and distribution centers, including headcount reductions and reorganization to drive a solution based approach, focusing commercial sales on competencies and product assortment gained from our recent acquisitions.

During the three months ended September 30, 2023, we recorded a net restructuring benefit of \$0.2 million for the first phase of the Restructuring Plan, primarily due to reversing an immaterial restructuring accrual. For the nine months ended September 30, 2023, we recorded net pre-tax charges of \$2.0 million which were primarily costs related to the relocation and termination of certain facilities in Canada. The restructuring charges are primarily recorded within Cost of goods sold on the condensed consolidated statements of operations. Total costs incurred relating to this first phase of the Restructuring Plan since it commenced from its commencement in the fourth quarter of 2022 are to its completion in 2023, were (i) \$6.4 million relating primarily to inventory markdowns, and (ii) \$3.2 million \$3.4 million relating primarily to the relocation and termination of certain facilities in Canada.

TABLE OF CONTENTS

As a result of the continued adverse market conditions, in the third quarter of 2023 we are implementing began a second phase of the Restructuring Plan, including U.S. manufacturing facility consolidations, in particular with respect to our production of certain

TABLE OF CONTENTS

durable equipment products. We plan to reduce are reducing facility space and consolidate consolidating our manufacturing operations in the U.S. to improve efficiency and reduce costs, while maintaining our high standard of customer service. During the three and nine months ended September 30, 2023, we recorded estimated pre-tax charges of \$7.8 million for the second phase of restructuring relating primarily to non-cash raw material inventory write-downs as we plan to sell the assets and reduce capacity and facility space, given low customer demand for these products. We also may evaluate other alternatives or opportunities to maximize our recovery of the inventory value. costs. These restructuring charges are primarily recorded within Cost of goods sold on the condensed consolidated statements of operations. During the three months ended March 31, 2024, we recorded pre-tax restructuring charges of \$0.1 million, relating primarily to cash charges associated with the consolidation of U.S. manufacturing facilities. Further, we we estimate additional additional charges associated with this second phase of the Restructuring Plan may exceed \$3.0 million \$2.0 million and be incurred through the next several quarters as we consolidate and exit facilities. These estimated additional charges include an estimated cash impact of approximately \$1.5 million that may exceed \$1.0 million for facility consolidations and lease and other contract terminations. We anticipate the second phase of our restructuring plan and related actions may result in cost savings of approximately \$1.5 million on an annualized basis. The amounts we will ultimately realize or disburse in connection with both phases of the Restructuring Plan could differ materially from our estimates, and we may not be able to realize the full extent of our anticipated cost savings.

As of June 30, 2022, primarily due to a sustained decline in the market value of our common stock and the market conditions described above, we identified a triggering event requiring a test for goodwill impairment. We completed our goodwill impairment testing and recorded an impairment charge of \$189.6 million as the test determined that the carrying value of the goodwill reporting units of U.S. and Canada was in excess of the fair value. The recognized impairment reduced the goodwill balance to zero as of June 30, 2022. The impairment was primarily due to a deterioration in customer demand in the United States and Canada caused by macroeconomic and industry conditions. We also review intangible assets with finite lives and indefinite lives for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. We noted a deterioration in customer demand in the United States and Canada caused by macroeconomic and industry conditions and fully impaired goodwill in 2022. However, we did not identify a triggering event requiring a test for impairment of intangible assets during the remainder of 2022, year ended December 31, 2023, or the nine three months ended September 30, 2023.

In connection with the goodwill impairment analysis performed as of June 30, 2022, we determined the fair value of the U.S. and Canada reporting units based on an income approach, using the present value of future discounted cash flows, and based on a market approach. The fair values were reconciled to the market value of our common stock to corroborate the estimates used in the interim test for impairment. The fair value determinations were a reflection of sales declines we experienced, which we believe were primarily a result of an agricultural oversupply impacting our market, and a reduction to our profitability and loss from operations. These market conditions continued to negatively impact our business and results of operations during the remainder of 2022, and the nine months ended September 30, 2023 March 31, 2024.

We maintain an allowance for excess and obsolete inventory that is based upon assumptions about future demand and market conditions. While we believe our estimates of charges relating to our Restructuring Plan, long-lived assets, inventory obsolescence, and accounts receivable allowances are reasonable, it is possible that we may incur additional charges in the future and actual results may differ significantly from these estimates and assumptions. Depending on the length and severity of the industry and market conditions impacting our business, it is possible we may execute additional restructuring plans plan actions and incur future associated charges, and we may not be able to realize the full extent of our anticipated cost savings.

Filing Status

As of June 30, 2023, the market capitalization of outstanding shares of our common stock owned by non-affiliates decreased to below \$60 million, which triggered the Company being classified as a non-accelerated filer with respect to SEC regulations and filing requirements effective December 31, 2023. As a result, our annual assessment of the effectiveness of our internal control over financial reporting does not require an audit by our external audit firm in compliance with the provisions of Section 404 of the Sarbanes-Oxley Act of 2002 for our next Annual Report on Form 10-K for the year ending December 31, 2023. The Company continues to qualify as a smaller reporting company in accordance with Rule 12b-2 under the Exchange Act and may continue to follow certain of the scaled back disclosure accommodations.

TABLE OF CONTENTS

Results of Operations—Comparison of three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023

The following table sets forth our unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2023 March 31, 2024, and 2022, 2023, including amounts and percentages of net sales for each period and the period-to-period change in dollars and percent (amounts in thousands):

	Three months ended September 30,						
	2023			2022			Period change
Net sales	\$	54,168	100.0 %	\$	74,155	100.0 %	\$ (19,987) -27.0 %
Cost of goods sold		50,859	93.9 %		68,291	92.1 %	(17,432) -25.5 %
Gross profit		3,309	6.1 %		5,864	7.9 %	(2,555) -43.6 %
Operating expenses:							

Selling, general and administrative	19,543	36.1 %	26,186	35.3 %	(6,643)	-25.4 %
Loss from operations	(16,234)	-30.0 %	(20,322)	-27.4 %	4,088	20.1 %
Interest expense	(3,963)	-7.3 %	(3,073)	-4.1 %	890	29.0 %
Other income, net	402	0.7 %	615	0.8 %	(213)	-34.6 %
Loss before tax	(19,795)	-36.5 %	(22,780)	-30.7 %	2,985	13.1 %
Income tax expense	(89)	-0.2 %	(759)	-1.0 %	(670)	-88.3 %
Net loss	\$ (19,884)	-36.7 %	\$ (23,539)	-31.7 %	\$ 3,655	15.5 %

Nine months ended September 30,												
		2023	2022	Period change								
Three months ended March 31,												
		2024										
		2024										
		2024										
Net sales												
Net sales												
Net sales	Net sales	\$179,397	100.0 %	\$ 283,040	100.0 %	\$(103,643)	-36.6 %	\$ 54,172	100.0	100.0	%	\$62,178
Cost of goods sold	Cost of goods sold	150,234	83.7 %	253,231	89.5 %	(102,997)	-40.7 %	Cost of goods sold	43,247	79.8	79.8	50,797
Gross profit	Gross profit	29,163	16.3 %	29,809	10.5 %	(646)	-2.2 %	Gross profit	10,925	20.2	20.2	11,381
Operating expenses:	Operating expenses:											
Selling, general and administrative	Selling, general and administrative	67,442	37.6 %	92,407	32.6 %	(24,965)	-27.0 %					
Impairments		—	0.0 %	192,328	68.0 %	(192,328)	-100.0 %					
Selling, general and administrative												
Selling, general and administrative												
Loss from operations	Loss from operations	(38,279)	-21.3 %	(254,926)	-90.1 %	216,647	85.0 %	Loss from operations	(8,696)	-16.1	-16.1	(13,050)
Interest expense	Interest expense	(11,423)	-6.4 %	(7,863)	-2.8 %	3,560	45.3 %	Interest expense	(3,931)	-7.3	-7.3	(3,692)
Other income, net	Other income, net	22	0.0 %	971	0.3 %	(949)	-97.7 %	Other income, net	215	0.4	0.4	40
Loss before tax	Loss before tax	(49,680)	-27.7 %	(261,818)	-92.5 %	212,138	81.0 %	Loss before tax	(12,412)	-22.9	-22.9	(16,702)
Income tax benefit		82	0.0 %	11,671	4.1 %	(11,589)	-99.3 %					
Income tax expense												
Income tax expense												
Net loss	Net loss	\$ (49,598)	-27.6 %	\$ (250,147)	-88.4 %	\$ 200,549	80.2 %	Net loss	\$ (12,608)	-23.3	-23.3	\$ (16,849)

Net sales

Net sales for the three months ended September 30, 2023 March 31, 2024, were \$54.2 million, a decrease of \$20.0 million \$8.0 million, or 27.0% 12.9% compared to the same period in 2022. Net sales for the nine months ended September 30, 2023, were \$179.4 million, a decrease of \$103.6 million, or 36.6% compared to the same period in 2022, 2023.

The 27.0% 12.9% decrease in net sales for the three months ended September 30, 2023 March 31, 2024, as compared to the same period in 2022, 2023, was due to a 22% 12.6% decline in volume volume/mix of products sold and a 5% 0.3% decrease in price and mix of products sold. price. The decrease in volume volume/mix of products sold was primarily related to the aforementioned oversupply in the cannabis industry. During

Gross profit

Gross profit for the three months ended September 30, 2023 March 31, 2024, we reduced selling prices for certain brands and product segments and sold was \$10.9 million, a higher mix decrease of generally lower-priced consumables relative to higher-priced durable products.

The 36.6% decrease in net sales for the nine months ended September 30, 2023 \$0.5 million, as or 4.0%, compared to the same period in 2022, 2023. The decrease was due to a 34% decline in volume of products sold and a 2% decrease in price and mix of products sold. The decrease in volume of products sold was primarily related lower net sales. Our gross profit margin percentage increased to the aforementioned oversupply in the cannabis industry. During the nine months ended September 30, 2023, we sold a higher mix of generally lower-priced consumables relative to higher-priced durable products, and reduced selling prices for certain brands and product segments, including previously reserved lighting products.

[TABLE OF CONTENTS](#)

Gross profit

Gross profit for the three months ended September 30, 2023, was \$3.3 million, a decrease of \$2.6 million, or 43.6%, compared to the same period in 2022. Gross profit for the nine months ended September 30, 2023, was \$29.2 million, a decrease of \$0.6 million, or 2.2%, compared to the same period in 2022.

Gross profit decreased \$2.6 million for the three months ended September 30, 2023, as compared to the same period in 2022, primarily due to (i) lower net sales, (ii) \$7.4 million of estimated restructuring charges recorded in the current year, primarily due to non-cash inventory markdowns, and partially offset by (iii) \$4.4 million of inventory reserves and related charges recorded in the prior year period, and (iv) benefits from selling a higher proportion of proprietary brand products, lower freight costs, and improved productivity. Our Restructuring Plan and related cost-saving initiatives contributed to realizing these benefits. Due to non-cash charges in both periods, including the aforementioned inventory markdowns, reserves, and related charges, our gross profit margin percentage (gross profit as a percent of net sales) decreased to 6.1% 20.2% for the three months ended September 30, 2023 March 31, 2024, from 7.9% 18.3% in the same period in 2022.

Gross profit decreased \$0.6 million for the nine months ended September 30, 2023, 2023, primarily as compared to the same period in 2022, primarily due to (i) lower net sales, (ii) \$9.4 million a result of estimated our restructuring charges recorded in the current year, primarily due to non-cash inventory markdowns, and partially offset by (iii) \$17.8 million of inventory reserves and related charges recorded cost savings initiatives which drove improved productivity in the prior year period, (iv) \$4.5 million decrease in acquisition and integration expenses, and (v) benefits from selling a higher proportion of proprietary brand products, lower freight costs, and improved productivity. Our Restructuring Plan and related cost-saving initiatives contributed to realizing these benefits. Our gross profit margin percentage increased to 16.3% for the nine months ended September 30, 2023, from 10.5% in the same period in 2022, manufacturing.

Selling, general and administrative expenses

Selling, general and administrative ("SG&A") &A expenses for the three months ended September 30, 2023 March 31, 2024, were \$19.5 million \$19.6 million, a decrease of \$6.6 million \$4.8 million, or 25.4% 19.7% compared to the same period in 2022. SG&A expenses for the nine months ended September 30, 2023, were \$67.4 million, a 2023. The decrease of \$25.0 million compared to the same period in 2022.

SG&A expenses decreased \$6.6 million for the three months ended September 30, 2023, as compared to the same period in 2022. SG&A expenses decreased in several areas, including as a result of our cost saving and restructuring initiatives: (i) \$1.8 million decrease in accounts receivable reserves and related charges, (ii) \$1.5 million decrease in salaries and benefits, (iii) \$0.9 million decrease in professional and outside services, (iv) \$0.7 million decrease in acquisition and integration expenses, (v) \$0.6 million decrease in stock-based compensation expense, (vi) \$0.4 million decrease in amortization and depreciation expenses, and (vii) \$0.3 million decrease in insurance expenses, along with other expense reductions in multiples areas.

The \$25.0 million decrease in SG&A expenses for the nine months ended September 30, 2023, as compared to the same period in 2022, was primarily related to a \$9.3 million decline in amortization and depreciation expenses, as the prior year period included additional amortization expense due to adjustments to the useful lives of intangible assets, as described in Note 2 – Basis of Presentation and Significant Accounting Policies. Additionally, SG&A expenses decreased by \$15.7 million in the nine months ended September 30, 2023, due to lower expenses in several areas, including as a result of our cost saving and restructuring initiatives: (i) \$4.1 million \$1.4 million decrease in salaries and benefits, facility costs, (ii) \$2.8 million decrease in stock-based compensation, (iii) \$2.6 million decrease in acquisition and integration expenses, (iv) \$1.8 million \$1.0 million decrease in professional and outside services, (v) \$1.8 million (iii) \$0.8 million decrease in accounts receivable reserves insurance costs, and related charges, (vi) \$1.4 million (iv) \$0.8 million decrease in costs associated with the relocation of certain of our distribution centers incurred last year, salaries and (vii) \$0.7 million decrease in marketing expenses, benefits, along with other expense reductions in multiples multiple areas.

Impairments

The Company did not record any impairment charges for the three and nine months ended September 30, 2023. The Company recorded a goodwill impairment charge of zero and \$189.6 million for the three and nine months ended September 30, 2022, as we determined that the carrying value of the goodwill reporting units of the U.S. and Canada was in excess of the fair value. The recognized impairment reduced the goodwill balance to zero as of June 30, 2022. The impairment was primarily due to a deterioration in customer demand in the United States and Canada caused by macroeconomic and industry conditions. For the nine months ended September 30, 2022, the Company also recorded, in the fiscal first quarter, an impairment of a note receivable of \$2.6 million. Refer to Note 2 – Basis of Presentation and Significant Accounting Policies and Note 14 – Fair Value Measurements for further description regarding the note receivable impairment.

[TABLE OF CONTENTS](#)

Interest expense

Interest expense for the three months ended September 30, 2023 March 31, 2024, was \$4.0 million \$3.9 million, an increase of \$0.9 million compared to the same period in the prior year. Interest expense for the nine months ended September 30, 2023, was \$11.4 million, an increase of \$3.6 million \$0.2 million compared to the same period in the prior year. The increase was primarily due to higher variable interest rates on our Term Loan.

Other income, net

Other income, net for the three months ended September 30, 2023 March 31, 2024, was \$0.4 million \$0.2 million, a decrease an increase of \$0.2 million compared to the same period in the prior year. Other income, net for the nine three months ended September 30, 2023, was less than \$0.1 million, a decrease of \$0.9 million compared to the same period in the prior year. Other income, net for the three and nine months ended September 30, 2023 March 31, 2024, was primarily driven by interest income and foreign currency exchange rate gains and interest income, partially offset by legal fees associated with the amendment of the Term Loan. Refer to Note 9 – Debt for a further description of the Term Loan amendment gains.

Income taxes

We recorded income tax expense of \$0.1 million \$0.2 million for the three months ended September 30, 2023 March 31, 2024, representing an effective tax rate of (0.4) (1.6)%. We recorded an income tax benefit of \$0.1 million for the nine months ended September 30, 2023, representing an effective income tax rate of 0.2%. Our effective tax rate for the nine three months ended September 30, 2023 March 31, 2024, differs from the federal statutory rate of 21% primarily due to maintaining a full valuation allowance against our net deferred tax assets in the United States and most foreign jurisdictions. The income tax expense and benefit for the three and nine months ended September 30, 2023 March 31, 2024, respectively, was primarily due to minor U.S. state taxes and foreign tax items taxes in certain jurisdictions.

We recorded an income tax expense of \$0.8 million \$0.1 million for the three months ended September 30, 2022, representing an effective tax rate of (3.3)%. We recorded an income tax benefit of \$11.7 million for the nine months ended September 30, 2022 March 31, 2023, representing an effective income tax rate of 4.5% (0.9)%. Our effective tax rate for the nine three months ended September 30, 2022 March 31, 2023, differs from the federal statutory rate of 21% primarily due to the impairment of goodwill for certain 2021 acquisitions which was not deductible for U.S. tax purposes, increases in our Company maintaining a full valuation allowance on U.S. against its net deferred tax assets in the U.S. and most foreign jurisdictions. The income tax expense for the establishment of a valuation allowance for Canadian deferred tax assets, three months ended March 31, 2023, was primarily due to foreign taxes in certain jurisdictions.

Liquidity and Capital Resources

Cash Flow from Operating, Investing, and Financing Activities

Comparison of the nine three months ended September 30, 2023 March 31, 2024, and September 30, 2022 March 31, 2023

The following table summarizes our cash flows for the nine three months ended September 30, 2023 March 31, 2024, and 2022 2023 (amounts in thousands):

	Nine months ended September 30,	
	2023	2022
Net cash from operating activities	\$ 8,629	\$ 15,490
Net cash used in investing activities	(4,058)	(7,386)
Net cash from (used in) financing activities	6,644	(19,480)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(49)	(515)
Net increase (decrease) in cash, cash equivalents and restricted cash	11,166	(11,891)
Cash, cash equivalents and restricted cash at beginning of period	21,291	28,384
Cash, cash equivalents and restricted cash at end of period	\$ 32,457	\$ 16,493

	Three months ended March 31,	
	2024	2023
Net cash used in operating activities	\$ (2,297)	\$ (8,950)
Net cash used in investing activities	(1,408)	(1,602)
Net cash (used in) from financing activities	(2,358)	7,959
Effect of exchange rate changes on cash and cash equivalents	(97)	5
Net decrease in cash and cash equivalents	(6,160)	(2,588)
Cash and cash equivalents at beginning of period	30,312	21,291
Cash and cash equivalents at end of period	\$ 24,152	\$ 18,703

Operating Activities

Net cash from used in operating activities was \$8.6 million \$2.3 million for the nine three months ended September 30, 2023, driven by positive March 31, 2024. Consistent with historical seasonal trends, we utilized cash from operating activities in the second and third quarters, first quarter to fund our working capital. The net cash from operating

activities was primarily due to a \$11.7 million net cash inflow from a reduction in working capital, partially offset by a reported net loss of \$49.6 million less non-cash items of \$46.6 million. The \$1.3

[TABLE OF CONTENTS](#)

million net reduction in working capital was primarily driven by decreases a \$5.7 million increase of inventories accounts receivable and a \$2.0 million decrease of \$22.6 million lease liabilities, partially offset by a \$4.2 million increase of accounts payable and prepaid accrued expenses and other current assets liabilities and a \$2.2 million decrease of \$1.2 million inventory.

Net cash used in operating activities was \$9.0 million for the three months ended March 31, 2023, primarily due to a net loss of \$16.8 million, partially offset by net non-cash items. Additionally, we had a \$5.5 million net cash usage for working capital. This was primarily due to an increase of \$5.1 million in accounts receivable, net, and decreases of \$7.0 million of lease liabilities and \$4.4 million \$3.1 million of accrued expenses and other current liabilities.

[TABLE OF CONTENTS](#)

Net cash from operating activities was \$15.5 million for the nine months ended September 30, 2022, primarily due to \$22.7 million net cash inflow from a reduction liabilities, \$2.2 million of working capital. This included lease liabilities, and \$1.1 million in deferred revenue, partially offset by a decrease of \$37.1 million \$7.3 million in inventories and a decrease of \$13.1 million in accounts receivable, net, partially offset by decreases of \$11.0 million in deferred revenue and \$11.0 million in accounts payable, accrued expenses and other current liabilities. inventories.

Investing Activities

Net cash used in investing activities was \$4.1 million \$1.4 million and \$7.4 million \$1.6 million for the nine three months ended September 30, 2023 March 31, 2024, and September 30, 2022 March 31, 2023, respectively, primarily due to capital expenditures of property, plant and equipment.

Financing Activities

Net cash used in financing activities was \$2.4 million for the three months ended March 31, 2024, primarily driven by \$2.0 million of Term Loan repayments relating to required quarterly payments of principal and prepayments made in conjunction with the Sale-Leaseback Transaction.

Net cash from financing activities was \$6.6 million \$8.0 million for the nine three months ended September 30, 2023 March 31, 2023, primarily driven by \$8.6 million of proceeds from the Sale-Leaseback Transaction. In addition, we paid \$0.9 million on the Term Loan relating to required quarterly payments of principal.

Net cash used in financing activities was \$19.5 million for the nine months ended September 30, 2022, primarily consisting of \$15.6 million in payments to settle contingent consideration. We paid \$2.4 million related to employees' withholding tax in connection with the vesting of restricted stock units. In addition, we paid \$0.9 million on the Term Loan.

Availability and Use of Cash

Our ability to make investments in our business, service our debt and maintain liquidity will depend upon our ability to generate excess operating cash flows through our operating subsidiaries. We believe that our cash flows from operating activities, combined with current cash levels and borrowing availability under the Revolving Credit Facility, will be adequate to support our ongoing operations, to fund debt service requirements, capital expenditures, lease obligations and working capital needs through the next twelve months of operations. However, we cannot guarantee that our business will generate sufficient cash flow from operating activities or that future borrowings will be available under our borrowing agreements in amounts sufficient to pay indebtedness or fund other working capital needs. Actual results of operations will depend on numerous factors, many of which are beyond our control as further discussed in *Item 1A. Risk Factors* included in this [Quarterly Report on Form 10-Q](#) and in our [2022 2023 Annual Report on Form 10-K. Report](#).

If necessary, we believe that we could supplement our cash position through additional sale-leasebacks, asset sales and equity financing. We believe it is prudent to be prepared if required and, accordingly, continue to be engaged in the process of evaluating and preparing to implement one or more of the aforementioned activities. Any potential such event may be subject to provisions referenced in our Term Loan and Revolving Credit Facility, such as subjecting the Company to making mandatory prepayments.

In January 2023, Gotham Properties LLC, an Oregon limited liability company and our subsidiary ("Seller"), consummated a Purchase and Sale Agreement with J & D Property, LLC, a Nevada limited liability company ("Purchaser") pursuant to which certain real property located in the City of Eugene, County of Lane, State of Oregon (the "Eugene Property") was sold to Purchaser for \$8.6 million and then leased back by Seller. The new lease has a term of 15 years with annual rent starting at approximately \$0.7 million and increases to the final year when annual rent is approximately \$1.0 million. The Eugene Property serves as the manufacturing and processing site for certain of our grow media and nutrient brands. Refer to further discussion below relating to Term Loan reinvestment provisions regarding the net cash proceeds of the Sale Leaseback Transaction.

If necessary, we believe that we could supplement our cash position through additional sale-leasebacks, asset sales and equity financing. We believe it is prudent to be prepared if required and, accordingly, continue to be engaged in the process of evaluating and preparing to implement one or more of the aforementioned activities. Any potential such event may be subject to provisions referenced in our Term Loan and Revolving Credit Facility, such as subjecting the Company to making mandatory prepayments.

Term Loan

On October 25, 2021, we and certain of our direct and indirect subsidiaries entered into the Term Loan with JPMorgan Chase Bank, N.A., as administrative agent for the lenders, pursuant to which we borrowed a \$125 million senior secured term loan, loan (the "Term Loan"). The Term Loan was amended by Amendment No. 1 effective as of June 27, 2023, to replace the LIBOR referenced rates with SOFR referenced rates. Pursuant to Amendment No. 1, any Term Loan that constitutes a Eurodollar Rate Loan that is outstanding as of the Amendment No. 1 closing date shall continue until the end of the applicable interest period for such Eurodollar Rate Loan and the provisions of the Term Loan applicable

thereto shall continue and remain in effect (notwithstanding the occurrence of the Amendment No. 1 closing date) until the end of the applicable interest period for such Eurodollar Rate Loan, after which such provisions shall have **had** no further force or effect. Such Eurodollar Rate Loan

[TABLE OF CONTENTS](#)

shall subsequently either be an ABR Loan or a Term Benchmark Loan. The ABR Loans shall bear interest at the Alternate Base Rate (with a 2.0% floor) plus 4.50%, and Term Benchmark Loans shall bear interest at the Adjusted Term SOFR Rate (with a 1.0% floor) plus 5.50%. **The As of the date of filing this Quarterly Report on Form 10-Q, the ABR Loan and Term Benchmark Loan credit spreads of 4.50% and 5.50%, respectively, within the**

[TABLE OF CONTENTS](#)

Amendment No. 1 have not changed from the credit spreads in the original Term Loan. The Term Loan matures on October 25, 2028.

The principal amounts of the Term Loan are scheduled to be repaid in consecutive quarterly installments in amounts equal to 0.25% of the original principal amount of the Term Loan on the last day of each fiscal quarter commencing March 31, 2022, with the balance of the Term Loan payable on the Maturity Date of October 25, 2028.

We are also required to make mandatory prepayments in the event of (i) achieving certain excess cash flow criteria, including the achievement and maintenance of a specific leverage ratio, (ii) certain asset sales that are collateral, or (iii) upon the issuance, offering, or placement of new debt obligations. As described in Note 6 – **intend to reinvest the Leases, we received** net cash proceeds **received** in January 2023 from the Sale-Leaseback Transaction and are subject to a provision whereby such net cash proceeds can be reinvested into certain **permitted** investments, such as capital expenditures. This provision of the Term Loan includes (i) cash investments made within a one-year period from the Sale Leaseback Transaction, and **includes (ii)** investments which are contractually committed within one-year **of the Sale Leaseback Transaction**, and paid within 180 days after entering into such contractual commitment. **If applicable, the** **The** amount of any net cash proceeds which are not reinvested would require us to make an offer to prepay the corresponding amount on the Term Loan **in 2024. In accordance with this provision, we classified \$1.7 million as current debt on our consolidated balance sheet as of December 31, 2023, and prepaid the Term Loan in this amount during the three months ended March 31, 2024. In addition, we had \$2.2 million of contractual commitments pursuant to this provision as of December 31, 2023. Should any of the \$2.2 million of contractual commitments not be paid within 180 days of their contractual commitment dates, we will be required to make an additional offer to prepay the corresponding amount in 2024. The foregoing description of the reinvestment provision does not purport to be complete and is qualified in its entirety by reference to the provisions of the Term Loan.**

As of March 31, 2024, and December 31, 2023, the outstanding principal balance on the Term Loan was \$120.5 million and \$122.5 million, respectively.

The Term Loan requires us to maintain certain reporting requirements, affirmative covenants, and negative covenants. We were in compliance with all debt covenants as of **September 30, 2023 March 31, 2024**. The Term Loan is secured by a first lien on our non-working capital assets and a second lien on our working capital assets.

Revolving Credit Facility

On March 29, 2021, we **and certain of our subsidiaries** entered into the Revolving Credit Facility **which provided (the "Revolving Credit Facility") with JPMorgan Chase Bank, N.A., as administrative agent, issuing bank and swingline lender for a borrowing limit revolving line of credit up to \$50 million.** The Revolving Credit Facility was amended by the First Amendment dated August 31, 2021, which increased the revolving line of credit by an additional \$50 million for an aggregate borrowing limit of \$100 million. The Revolving Credit Facility was further amended by the Second Amendment dated October 25, 2021 which, among other things, permitted the incurrence of the Term Loan and made certain other changes including subordinating its liens on non-working capital assets to the obligations under the Term Loan. The Revolving Credit Facility was further amended by the Third Amendment and Joinder dated August 23, 2022, pursuant to which several previously acquired subsidiaries became parties to the Revolving Credit Facility and granted liens on their assets. On December 22, 2022, **the Company we** entered into the Fourth Amendment pursuant to which a sale-leaseback transaction was permitted, and certain other changes were made, including a reduction of the maximum commitment amount under the Revolving Credit Facility from \$100 million to \$75 million and transitioning the LIBOR based rates to SOFR based rates. On March 31, 2023, **the Company we** and certain of **its our** subsidiaries entered into the Fifth Amendment, pursuant to which the maturity date was extended to June 30, 2026, the maximum commitment amount under the Revolving Credit Facility was reduced to \$55 million, and the interest rate on borrowings was revised to various spreads, based on **the Company's our** fixed charge coverage ratio.

The Revolving Credit Facility provides for various interest rate options including the Adjusted Term SOFR Rate, the Adjusted REVSOFR30 Rate, the CB Floating Rate, the Adjusted Daily Simple SOFR, the CBFR, the Canadian Prime Rate, or the CDOR Rate. The rates that use SOFR as the reference rate (Adjusted Term SOFR Rate, the Adjusted REVSOFR30 Rate, the Adjusted Daily Simple SOFR and the CBFR rate) use the Term SOFR Rate plus 1.95%. Each rate has a 0.0% floor. A fee of 0.40% per annum is charged for available but unused borrowings. Our obligations under the Revolving Credit Facility are secured by a first priority lien (subject to certain permitted liens) in substantially all of our and our subsidiaries' respective personal property assets pursuant to the terms of a U.S. and Canadian Pledge and Security Agreement dated March 29, 2021 and other security documents, as amended to include additional subsidiaries.

[TABLE OF CONTENTS](#)

The Revolving Credit Facility maintains certain reporting requirements, affirmative covenants, negative covenants and financial covenants. A certain financial covenant becomes applicable in the event that our excess availability under the Revolving Credit Facility is less than an amount equal to 10% of the Aggregate Revolving Commitment (currently \$55 million) and would require us to maintain a minimum fixed charge coverage ratio of 1.1x on a rolling twelve-month basis.

In order to consummate permitted acquisitions or to make restricted payments, the Company we would be required to comply with a higher fixed charge coverage ratio of 1.15x, but no such acquisitions or payments are currently contemplated.

We were in compliance with all debt covenants as of September 30, 2023 March 31, 2024. As of September 30, 2023 March 31, 2024, approximately \$28 \$25 million was available to borrow under the Revolving Credit Facility, before the Company we would be required to comply with the minimum fixed charge coverage ratio of 1.1x.

As of September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, the Company we had zero borrowed under the Revolving Credit Facility.

TABLE OF CONTENTS

The aforementioned financing arrangements and other transactions are more fully described in the notes to the condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Cash and cash equivalents Cash Equivalents

The cash and cash equivalents balances of \$32.5 million \$24.2 million and \$21.3 million \$30.3 million at September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, respectively, included \$11.7 \$7.1 million and \$7.3 \$8.5 million, respectively, held by foreign subsidiaries.

Material Cash Requirements

Our material cash requirements include interest (i) principal repayments and principal anticipated interest payments on our long-term debt, and (ii) finance leases, lease payments, (iii) operating lease payments, and (iv) balances subject to the Term Loan reinvestment provision, as well as other purchase obligations to support our operations. Variable rates on our Term Loan are subject to change as further described in Item 3. Quantitative and Qualitative Disclosures About Market Risk. Refer to Part I, Item 1, 1. Financial Statements, Note 9 – Debt, Note 6 – Leases, and Note 13 – Commitments and Contingencies for details relating to our material cash requirements for debt, our leasing arrangements, including future maturities of our operating lease liabilities, and purchase obligations, respectively.

From time to time in the normal course of business, we will enter into agreements with suppliers which provide favorable pricing in return for a commitment to purchase minimum amounts of inventory over a defined time period.

Critical Accounting Policies and Estimates

The preceding discussion and analysis of our consolidated results of operations and financial condition should be read in conjunction with our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Our critical accounting policies and estimates are identified in Management's Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of our most recently filed Form 10-K the 2023 Annual Report and include the discussion of estimates used in goodwill and indefinite lived intangible assets, long-lived tangible and finite-lived intangible assets, and inventory valuation. Such accounting policies and estimates require significant judgments and assumptions to be used in the preparation of the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q, and actual results could differ materially from the amounts reported.

Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, refer to Note 2 – Basis of Presentation and Significant Accounting Policies — Recent accounting pronouncements, to our Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q.

TABLE OF CONTENTS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk is the risk of economic losses due to adverse changes in financial market prices and rates. Our primary market risk has been interest rate, foreign currency and inflation risk. We do not have material exposure to commodity risk.

Interest Rate Risk

We are exposed to interest rate risk through our variable rate debt. As of September 30, 2023 March 31, 2024, we had \$122.8 million \$120.5 million of Term Loan debt that is subject to variable interest rates that are based on Secured Overnight Financing Rate ("SOFR") or an alternate base rate. Refer to Part I, Item 1, 1. Financial Statements, Note 9 – Debt for details relating to the debt. If the rates were to increase by 100 basis points from the rates in effect as of September 30, 2023 March 31, 2024, our interest expense on the variable-rate debt would increase by an average of \$1.1 million annually. There are inherent limitations in the sensitivity analysis presented, primarily due to the assumptions that interest rate changes would be instantaneous, while SOFR changes regularly. We do not currently hedge our interest rate risks, but may determine to do so in the future.

Foreign Currency Risk

The functional currencies of our foreign subsidiary operations are predominantly in the Canadian dollar ("CAD") and the Euro. For the purposes of presenting these condensed consolidated financial statements, the assets, and liabilities of subsidiaries with CAD or Euro functional currencies are translated into USD using exchange rates prevailing at the end of each reporting period. Income and expense items are translated at the average rate prevailing during the period with exchange differences impacting other comprehensive income (loss) in equity. Therefore, our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, principally the CAD. We are impacted by changes in foreign currency exchange rates when we sell product in currencies different from the currency in which costs were incurred. The functional currencies and our purchasing and sales activities primarily include USD, CAD and Euro. As these currencies fluctuate against each other, and other currencies, we are exposed to foreign currency exchange rate risk on sales, purchasing transactions, and labor. To date, we have not entered into any foreign currency exchange contracts and currently do not expect to enter into foreign currency exchange contracts for trading or speculative purposes.

Impact of Inflation

Our results of operations and financial condition are presented based on historical costs. We cannot provide assurances that our results of operations and financial condition will not be materially impacted by inflation in the future.

[TABLE OF CONTENTS](#)

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Company's management, including the Chief Executive Officer and the Chief Financial Officer, concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this Quarterly Report on Form 10-Q.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

[TABLE OF CONTENTS](#)

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. We are currently not aware of any legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

ITEM 1A. RISK FACTORS

For a discussion of risk factors, please read Item 1A, "Risk Factors" in our 2022 2023 Annual Report. Such risk factors continue to be relevant to an understanding of our business, financial condition and operating results. As of the date of this Quarterly Report on Form 10-Q, there have been the following material changes with respect to such risk factors.

Failures at financial institutions at If we fail to meet the continued listing standards of Nasdaq, our common stock may be delisted, which we maintain or deposit funds, or at which parties with whom we conduct business maintain funds, could adversely affect us.

We deposit funds in financial institutions and may, from time to time, maintain cash balances at such financial institutions in excess of the Federal Deposit Insurance Corporation ("FDIC") Limit of \$250,000. Recently there has been significant volatility and instability among banks and financial institutions. For example, on March 10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and for a period of time, customers of the bank did not have access to their funds and there was uncertainty as to when, if at all, customers would have access to funds in excess of the FDIC insured amounts. Should a financial institution at which deposits are maintained fail, there is no guarantee as to the extent that we would recover the funds deposited, whether through FDIC coverage or otherwise, or the timing of any recovery. In addition, if any parties with whom we conduct business are unable to access funds pursuant to arrangements with their financial institution, such parties' ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected.

Our restructuring activities may increase our expenses and cash expenditures, and may not have the intended effects.

In connection with the Restructuring Plan, we have implemented and may continue to implement a number of restructuring initiatives designed to streamline our operations, reduce costs, and improve efficiencies during the industry recession. See "Item 2. Management's Discussion And Analysis Of Financial Condition And Results of Operations – Market Conditions" above for more information regarding the Restructuring Plan. Restructuring initiatives such as the Restructuring Plan typically result in charges and cash expenditures that may adversely affect the market price and liquidity of our common stock.

Our common stock is currently traded on The Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq requires us to meet certain financial, results public float, bid price and liquidity standards on an ongoing basis in order to continue the listing of our common stock, including that we maintain a minimum closing bid price of \$1.00 per share (the "Minimum Bid Price Requirement").

On March 14, 2024, we received written notice from the Listing Qualifications Department of Nasdaq notifying us that for one the preceding 30 consecutive business days, our common stock did not maintain compliance with the Minimum Bid Price Requirement. The notice had no immediate effect on the listing or more periods, trading of our common stock, which has continued to trade on The Nasdaq Global Select Market under the symbol "HYFM."

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a grace period of 180 calendar days, or until September 10, 2024 (the "Compliance Period"), to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance can be achieved automatically and efforts to minimize without further action if the closing bid price of our common stock is at or eliminate such expenditures may above \$1.00 for a minimum of 10 consecutive business days at any time during the Compliance Period, in which case Nasdaq will notify us of our compliance and the matter will be closed.

If, however, we do not be successful. Moreover, restructuring actions can create unanticipated consequences, such as instability or distraction among our workforce or among management.

We cannot assure you that achieve compliance with the Restructuring Plan or any other cost-saving initiatives Minimum Bid Price Requirement during the Compliance Period, we may undertake be eligible for additional time to comply. In order to be eligible for such additional time, we will be successful. A variety required to meet the continued listing requirement for market value of factors, many publicly held shares and all other Nasdaq initial listing standards, with the exception of which are beyond the Minimum Bid Price Requirement, and must notify Nasdaq in writing of our control, could cause us not intention to realize expected cost savings, including but not limited cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary.

There can be no assurance that we will be able to unexpected costs incurred in connection regain compliance with consolidating and/ the Minimum Bid Price Requirement during the Compliance Period or closing certain operations or asset write-downs, delays or difficulty terminating leases, unexpected integration challenges, unintended attrition that we will be able to maintain compliance with the other requirements for continued listing of our common stock on Nasdaq. If our common stock is delisted and temporary instability. Any of these factors could hamper our ability to grow and meet customer demand in future periods. If we are unable to structure list our operations in the light of evolving market conditions, common stock on another U.S. national securities exchange, we expect our securities would be quoted on an over-the-counter market. If this were to occur, our stockholders could have a face significant material adverse effect on consequences, including limited availability of market quotations for our business, financial condition, results common stock and reduced liquidity for the trading of operations, and cash flows.

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the military conflict between Russia and Ukraine and armed conflicts between Israel and Hamas. Our business, financial condition and results of operations may be materially and adversely affected by any negative impact on the global economy and capital markets resulting from the conflicts in Ukraine, the Gaza Strip or any other geopolitical tensions.

U.S. and global markets have experienced volatility and disruption following the escalation of geopolitical tensions, including the military conflict between Russia and Ukraine and armed conflicts between Israel and Hamas. Although the length and impact of the ongoing conflicts is highly unpredictable, such conflicts could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. We are continuing to monitor the situations in Ukraine, the Gaza Strip and globally and assessing their potential impacts on our business. In addition, sanctions on Russia and hostilities involving Israel securities. Furthermore, if our common stock were delisted it could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us our ability to obtain additional funds. financing for the continuation of our operations and/or result in the loss of confidence by investors, customers, suppliers and employees.

Any of the above mentioned factors could affect our business, prospects, financial condition, and operating results. The extent and duration of the military actions, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in our 2022 Annual Report.

[TABLE OF CONTENTS](#)

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

[TABLE OF CONTENTS](#)

ITEM 5. OTHER INFORMATION

None. On May 10, 2024, Innovative Growers Equipment, Inc., a wholly-owned indirect subsidiary of the Company ("IGE"), Manufacturing & Supply Chain Services, Inc., a wholly-owned indirect subsidiary of the Company ("MSCSI" and collectively with IGE, the "Sellers"), CM Fabrication, LLC (the "Buyer") and Chris Mayer, Senior Vice President of Commercial Sales of the Company, entered into an Asset Purchase Agreement (the "Purchase Agreement") pursuant to which IGE and MSCSI agreed to sell certain assets relating to the production of durable equipment products, including inventories, property, plant and equipment, and other assets, owned by the Sellers (the "Certain Assets") to the Buyer for approximately \$8.7 million (the "Asset Sale"). The Asset Sale is expected to close (the "Closing") in the second quarter of 2024, subject to customary closing conditions (such date of closing, the "Closing Date").

The Purchase Agreement includes certain confidentiality, non-competition, non-solicitation and non-disparagement provisions applicable to the Buyer and Mr. Mayer for a period beginning on the Closing Date and ending on the later of (i) the term of the Supply Agreement (as defined below) and (ii) the term of the Consulting Agreement (as defined below), and, in certain circumstances, may be the later of (i) the fourth anniversary of the Closing Date, (ii) the term of the Supply Agreement and (iii) the term of the Consulting Agreement. Additionally, pursuant to the Purchase Agreement, subject to limited exceptions, the Company has a right of first refusal with respect to any sale by the Buyer of all or

substantially all of the Certain Assets for a period beginning on the Closing Date and ending on the later of (i) the eighth anniversary of the Closing Date and (ii) the term of the Supply Agreement. The Purchase Agreement includes other customary representations, warranties and covenants regarding the Sellers and the Buyer.

At the Closing, the Buyer and Hydrofarm will enter into an exclusive supply agreement, pursuant to which the Buyer will continue to supply substantially all of the products historically made in the Company's manufacturing facility, including horticulture benches, racking and LED lighting systems, to the Sellers for an initial term of five years (the "Supply Agreement").

In addition, at the Closing the Company and Mr. Mayer will enter into a Consulting Agreement, pursuant to which Mr. Mayer will provide consulting services to the Company for a five-year period (the "Consulting Agreement"). Such consulting services shall relate to sales and business development efforts. In connection with the Consulting Agreement, Mr. Mayer will resign from his position at the Company.

Pursuant to the Term Loan, the Company is required to either reinvest the net proceeds from the Asset Sale into certain permitted investments, such as capital expenditures, or offer to prepay Term Loan principal. In connection with the Asset Sale, the Company intends to pay in full and terminate a facility operating lease for approximately \$1.3 million and certain finance leases for approximately \$0.7 million.

The foregoing descriptions of the Purchase Agreement do not purport to be complete and are qualified in their entirety by reference to the Purchase Agreement, which will be filed as an exhibit to the Company's quarterly report on Form 10-Q for the period ending June 30, 2024.

TABLE OF CONTENTS

ITEM 6. EXHIBITS

(a) Exhibits.

Exhibit	Description
10.1 10.1*+	Fifth Amendment to Credit Agreement, dated March 31, 2023, by and among Hydrofarm Holdings Group, Inc., Hydrofarm, LLC, Field 16, LLC, Innovative Growers Equipment, Inc., Manufacturing & Supply Chain Services, Inc., Hydrofarm Investment Corp., Hydrofarm Holdings LLC, EHH Holdings, LLC, Sunblaster LLC, Hydrofarm Canada, LLC, Sunblaster Holdings ULC, Eddi's Wholesale Garden Supplies Ltd., House & Garden Holdings, LLC, Gotham Properties LLC, Aurora International, LLC, Aurora Peat Products ULC, Greenstar Plant Products Inc., Innovative AG Installation, Inc., Innovative Racking Systems, Inc., Innovative Shipping Solutions, Inc., Innovative Growers Equipment Canada, Inc., JPMorgan Chase Bank, N.A., as lender, and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on April 6, 2023).
10.2	Amendment No. 1 to Credit and Guaranty Agreement, dated as of June 27, 2023, by and among Hydrofarm Holdings Group, Inc., the subsidiaries of Hydrofarm Holdings Group, Inc. party thereto from time to time, the lenders party thereto and JP Morgan Chase Bank, N.A., as administrative agent and as collateral Agent. (Incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the SEC on July 3, 2023). 2020 Equity Incentive Plan Stock Option Grant Notice.
10.2*+	Form of Hydrofarm Holdings Group, Inc. 2020 Equity Incentive Plan Restricted Stock Unit Grant Notice.
10.3*+	Form of Hydrofarm Holdings Group, Inc. 2020 Equity Incentive Plan Performance Stock Unit Grant Notice.
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*#	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*#	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101. INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	Inline XBRL Taxonomy Schema Linkbase Document.
101.CAL	Inline XBRL Taxonomy Calculation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Definition Linkbase Document.
101.LAB	Inline XBRL Taxonomy Labels Linkbase Document.
101.PRE	Inline XBRL Taxonomy Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

* Filed herewith.

+ Denotes management contract or compensatory plan or arrangement.

The certifications attached as Exhibits 32.1 and 32.2 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed "filed" by the Company for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 14, 2024

Hydrofarm Holdings Group, Inc.

/s/ William Toler

William Toler

Chief Executive Officer

(Principal Executive Officer)

Date: May 14, 2024

/s/ B. John Lindeman

B. John Lindeman

Executive Vice President & Chief Financial Officer

(Principal Financial Officer)

34

Exhibit 10.1

Option No. _____

HYDROFARM HOLDINGS GROUP, INC.
Stock Option Grant Notice
Stock Option Grant under the Company's
2020 Employee, Director and Consultant Equity Incentive Plan

1. Name and address of participant:

2. Grant date:

3. Type of grant:

4. Maximum number of shares for which this option is exercisable:

5. Exercise (purchase) price per share:

6. Option expiration date:

7. Vesting start date:

8. Vesting schedule: this option shall become exercisable (and the shares issued upon exercise shall be vested) as follows provided the Participant is an Employee, director or consultant of the Company or of an Affiliate on the applicable vesting date:

[Insert Vesting Schedule]

The foregoing rights are cumulative and are subject to the other terms and conditions of this Stock Option Grant Notice and the Plan.
The Company and the Participant acknowledge receipt of this Stock Option Grant Notice and agree to the terms of the Stock Option Agreement attached hereto and incorporated by reference herein, the Company's 2020 Employee, Director and Consultant Equity Incentive Plan and the terms of this Option Grant as set forth above.

HYDROFARM HOLDINGS GROUP, INC.

By:

Name:

Title:

Participant:

HYDROFARM HOLDINGS GROUP, INC.

STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS

AGREEMENT (this "Agreement") made as of the date of grant set forth in the Stock Option Grant Notice by and between Hydrofarm Holdings Group, Inc. (the "Company"), a Delaware corporation, and the individual whose name appears on the Stock Option Grant Notice (the "Participant").

WHEREAS, the Company desires to grant to the Participant an Option to purchase shares of its common stock, \$0.0001 par value per share (the "Shares"), under and for the purposes set forth in the Company's 2020 Employee, Director and Consultant Equity Incentive Plan (the "Plan");

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the same meanings as in the Plan; and

WHEREAS, the Company and the Participant each intend that the Option granted herein shall be of the type set forth in the Stock Option Grant Notice.

NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the parties hereto agree as follows:

1. **GRANT OF OPTION.** The Company hereby grants to the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth in the Stock Option Grant Notice, on the terms and conditions and subject to all the limitations set forth herein, under United States securities and tax laws, and in the Plan, which is incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan.

2. **EXERCISE PRICE.** The exercise price of the Shares covered by the Option shall be the amount per Share set forth in the Stock Option Grant Notice, subject to adjustment, as provided in the Plan, in the event of a stock split, reverse stock split or other events affecting the holders of Shares after the date hereof (the "Exercise Price"). Payment shall be made in accordance with Paragraph 10 of the Plan.

3. **EXERCISABILITY OF OPTION.** Subject to the terms and conditions set forth in this Agreement and the Plan, the Option granted hereby shall become vested and exercisable as set forth in the Stock Option Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan.

4. **TERM OF OPTION.** This Option shall terminate on the Option Expiration Date as specified in the Stock Option Grant Notice and, if this Option is designated in the Stock Option Grant Notice as an ISO and the Participant owns as of the date hereof more than 10% of the total combined voting power of all classes of capital stock of the Company or an Affiliate, such date may not be more than five years from the date of this Agreement, but shall be subject to earlier termination as provided herein or in the Plan.

If the Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate for any reason other than the death or Disability of the Participant, or termination of the Participant for Cause (the "Termination Date"), the Option to the extent then vested and exercisable pursuant to Section 3 hereof as of the Termination Date, and not previously terminated in accordance with this Agreement, may be exercised within three months after the Termination Date, or on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice, whichever is earlier, but may not be exercised thereafter except as set forth below. In such event, the unvested portion of the Option shall not be exercisable and shall expire and be cancelled on the Termination Date.

If this Option is designated in the Stock Option Grant Notice as an ISO and the Participant ceases to be an Employee of the Company or of an Affiliate but continues after termination of employment to provide service to the Company or an Affiliate as a director or Consultant, this Option shall continue to vest in accordance with Section 3 above as if this Option had not terminated until the Participant is no longer providing services to the Company. In such case, this Option shall automatically convert and be deemed a Non-Qualified Option as of the date that is three months from termination of the Participant's employment and this Option shall continue on the same terms and conditions set forth herein until such Participant is no longer providing service to the Company or an Affiliate.

Notwithstanding the foregoing, in the event of the Participant's Disability or death within three months after the Termination Date, the Participant or the Participant's Survivors may exercise the Option within one year after the Termination Date, but in no event after the Option Expiration Date as specified in the Stock Option Grant Notice.

In the event the Participant's service is terminated by the Company or an Affiliate for Cause, the Participant's right to exercise any unexercised portion of this Option even if vested shall cease immediately as of the time the Participant is notified his or her service is terminated for Cause, and this Option shall thereupon terminate. Notwithstanding anything herein to the contrary, if subsequent to the Participant's termination, but prior to the exercise of the Option, the Administrator determines that, either prior or subsequent to the Participant's termination, the Participant engaged in conduct which would constitute Cause, then the Participant shall immediately cease to have any right to exercise the Option and this Option shall thereupon terminate.

In the event of the Disability of the Participant, as determined in accordance with the Plan, the Option shall be exercisable within one year after the Participant's termination of service due to Disability or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be exercisable:

- (a) to the extent that the Option has become exercisable but has not been exercised as of the date of the Participant's termination of service due to Disability; and
- (b) in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of the Participant's termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration

shall be based upon the number of days accrued in the current vesting period prior to the date of the Participant's termination of service due to Disability. In the event of the death of the Participant while an Employee, director or Consultant of the Company or of an Affiliate, the Option shall be exercisable by the Participant's Survivors within one year after the date of death of the Participant or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be exercisable:

	Hydrofarm Holdings Group, Inc.	to the extent that the Option has become exercisable but has not been exercised as of the date of death; and
	(x)	
Date: November 9, 2023	/s/ William Toler	
(y)	William Toler	
	Chief Executive Officer (Principal Executive Officer) in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant's date of death.	

5. **METHOD OF EXERCISING OPTION.** Subject to the terms and conditions of this Agreement, the Option may be exercised by written notice to the Company or its designee, in substantially the form of Exhibit A attached hereto (or in such other form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which the Option is being exercised and shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in accordance with Paragraph 10 of the Plan. The Company shall deliver such Shares as soon as practicable after the notice shall be received, provided, however, that the Company may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company deems necessary under any applicable law (including, without limitation, state securities or "blue sky" laws). The Shares as to which the Option shall have been so exercised shall be registered in the Company's share register in the name of the person so exercising the Option (or, if the Option shall be exercised by the Participant and if the Participant shall so request in the notice exercising the Option, shall be registered in the Company's share register in the name of the Participant and another person jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person exercising the Option. In the event the Option shall be exercised, pursuant to Section 4 hereof, by any person other than the Participant, such notice shall be accompanied by appropriate proof of the right of such person to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and nonassessable.

6. **PARTIAL EXERCISE.** Exercise of this Option to the extent above stated may be made in part at any time and from time to time within the above limits, except that no fractional share shall be issued pursuant to this Option.

7. **NON-ASSIGNABILITY.** The Option shall not be transferable by the Participant otherwise than by will or by the laws of descent and distribution. If this Option is a Non-Qualified Option then it may also be transferred pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except as provided above in this paragraph, the Option shall be exercisable, during the Participant's lifetime, only by the Participant (or, in the event of legal incapacity or incompetency, by the Participant's guardian or representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of the Option or of any rights granted hereunder contrary to the provisions of this Section 7, or the levy of any attachment or similar process upon the Option shall be null and void.

8. **NO RIGHTS AS STOCKHOLDER UNTIL EXERCISE.** The Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until registration of the Shares in the Company's share register in the name of the Participant. Except as is expressly provided in the Plan with respect to certain changes in the capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the record date is prior to the date of such registration.

9. **ADJUSTMENTS.** The Plan contains provisions covering the treatment of Options in a number of contingencies such as stock splits and mergers. Provisions in the Plan for adjustment with respect to stock subject to Options and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

10. **TAXES.** The Participant acknowledges and agrees that (i) any income or other taxes due from the Participant with respect to this Option or the Shares issuable pursuant to this Option shall be the Participant's responsibility; (ii) the Participant was free to use professional advisors of his or her choice in connection with this Agreement, has received advice from his or her professional advisors in connection with this Agreement, understands its meaning and import, and is entering into this Agreement freely and without coercion or duress; (iii) the Participant has not received and is not relying upon any advice, representations or assurances made by or on behalf of the Company or any Affiliate or any employee of or counsel to the Company or any Affiliate regarding any tax or other effects or implications of the Option, the Shares or other matters contemplated by this Agreement; and (iv) neither the Administrator, the Company, its Affiliates, nor any of its officers or directors, shall be held liable for

any applicable costs, taxes, or penalties associated with the Option if, in fact, the Internal Revenue Service were to determine that the Option constitutes deferred compensation under Section 409A of the Code.

If this Option is designated in the Stock Option Grant Notice as a Non-Qualified Option or if the Option is an ISO and is converted into a Non-Qualified Option and such Non-Qualified Option is exercised, the Participant agrees that the Company may withhold from the Participant's remuneration, if any, to the extent permitted by applicable law, an amount sufficient to satisfy the federal, state, and local withholding tax requirements, both domestic and foreign, relating to such transaction, provided that such amount may not exceed the maximum statutory withholding rate. At the Company's discretion, the amount required to be withheld may be withheld in cash from such remuneration, or in kind from the Shares otherwise deliverable to the Participant on exercise of the Option. The Participant further agrees that, if the Company does not withhold an amount from the Participant's remuneration sufficient to satisfy the Company's income tax withholding obligation, the Participant will reimburse the Company on demand, in cash, for the amount under-withheld.

11. **PURCHASE FOR INVESTMENT.** Unless the offering and sale of the Shares to be issued upon the particular exercise of the Option shall have been effectively registered under the Securities Act, the Company shall be under no obligation to issue the Shares covered by such exercise unless the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act and until the following conditions have been fulfilled:

- (a) The person(s) who exercise the Option shall warrant to the Company, at the time of such exercise, that such person(s) are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person(s) acquiring such Shares shall be bound by the provisions of the following legend which shall be endorsed upon any certificate(s) evidencing the Shares issued pursuant to such exercise:
"The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws;" and
- (b) If the Company so requires, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular exercise in compliance with the Securities Act without registration thereunder. Without limiting the generality of the foregoing, the Company may delay issuance of the

Shares until completion of any action or obtaining of any consent, which the Company deems necessary under any applicable law (including without limitation state securities or "blue sky" laws).

12. RESTRICTIONS ON TRANSFER OF SHARES.

- (a) The Participant agrees that in the event the Company proposes to offer for sale to the public any of its equity securities and such Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares, then it will promptly sign such agreement and will not transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her during such period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with FINRA rules or similar rules

thereto promulgated by another regulatory authority (such period, the "Lock-Up Period"). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of the Lock-Up Period.

- (b) The Participant acknowledges and agrees that neither the Company, its stockholders nor its directors and officers, has any duty or obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following a termination of the service of the Participant by the Company, including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity.

13. NO OBLIGATION TO MAINTAIN RELATIONSHIP. The Participant acknowledges that: (i) the Company is not by the Plan or this Option obligated to continue the Participant as an employee, director or Consultant of the Company or an Affiliate; (ii) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (iii) the grant of the Option is a one-time benefit which does not create any contractual or other right to receive future grants of options, or benefits in lieu of options; (iv) all determinations with respect to any such future grants, including, but not limited to, the times when options shall be granted, the number of shares subject to each option, the option price, and the time or times when each option shall be exercisable, will be at the sole discretion of the Company; (v) the Participant's participation in the Plan is voluntary; (vi) the value of the Option is an extraordinary item of compensation which is outside the scope of the Participant's employment or consulting contract, if any; and (vii) the Option is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.

14. IF OPTION IS INTENDED TO BE AN ISO. If this Option is designated in the Stock Option Grant Notice as an ISO so that the Participant (or the Participant's Survivors) may qualify for the favorable tax treatment provided to holders of Options that meet the standards of Section 422 of the Code then any provision of this Agreement or the Plan which conflicts with the Code so that this Option would not be deemed an ISO is null and void and any ambiguities shall be resolved so that the Option qualifies as an ISO. The Participant should consult with the Participant's own tax advisors regarding the tax effects of the Option and the requirements necessary to obtain favorable tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements.

Notwithstanding the foregoing, to the extent that the Option is designated in the Stock Option Grant Notice as an ISO and is not deemed to be an ISO pursuant to Section 422(d) of the Code because the aggregate Fair Market Value (determined as of the Date of Option Grant) of any of the Shares with respect to which this ISO is granted becomes exercisable for the first time during any calendar year in excess of \$100,000, the portion of the Option representing such excess value shall be treated as a Non-Qualified Option and the Participant shall be deemed to have taxable income measured by the difference between the then Fair Market Value of the Shares received upon exercise and the price paid for such Shares pursuant to this Agreement.

Neither the Company nor any Affiliate shall have any liability to the Participant, or any other party, if the Option (or any part thereof) that is intended to be an ISO is not an ISO or for any action taken by the Administrator, including without limitation the conversion of an ISO to a Non-Qualified Option.

15. NOTICE TO COMPANY OF DISQUALIFYING DISPOSITION OF AN ISO. If this Option is designated in the Stock Option Grant Notice as an ISO then the Participant agrees to notify the Company in writing immediately after the Participant makes a Disqualifying Disposition of any of the Shares acquired pursuant to the exercise of the ISO. A Disqualifying Disposition is defined in Section 424(c) of the Code and includes any

disposition (including any sale) of such Shares before the later of (a) two years after the date the Participant was granted the ISO or (b) one year after the date the Participant acquired Shares by exercising the ISO, except as otherwise provided in Section 424(c) of the Code. If the Participant has died before the Shares are sold, these holding period requirements do not apply and no Disqualifying Disposition can occur thereafter.

16. NOTICES. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows:

If to the Company:

Hydrofarm Holdings Group, Inc.

Attention:

If to the Participant at the address set forth on the Stock Option Grant Notice or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given upon the earlier of receipt, one business day following delivery to a recognized courier service or three business days following mailing by registered or certified mail.

17. **GOVERNING LAW.** This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive jurisdiction in **[State]** and agree that such litigation shall be conducted in the state courts of **[County]**, **[State]** or the federal courts of the United States for the District of **[State]**.

18. **BENEFIT OF AGREEMENT.** Subject to the provisions of the Plan and the other provisions hereof, this Agreement shall be for the benefit of and shall be binding upon the heirs, executors, administrators, successors and assigns of the parties hereto.

19. **ENTIRE AGREEMENT.** This Agreement, together with the Plan, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof (with the exception of acceleration of vesting provisions contained in any other agreement with the Company). No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict, the express terms and provisions of this Agreement. Notwithstanding the foregoing in all events, this Agreement shall be subject to and governed by the Plan.

20. **MODIFICATIONS AND AMENDMENTS.** The terms and provisions of this Agreement may be modified or amended as provided in the Plan.

21. **WAIVERS AND CONSENTS.** Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

22. **DATA PRIVACY.** By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options and the administration of the Plan; (ii) to the extent permitted by applicable law waives any data privacy rights he or she may have with respect to

such information, and (iii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Exhibit A

**NOTICE OF EXERCISE OF STOCK OPTION
Form for Shares registered in the United States**

To: Hydrofarm Holdings Group, Inc.

IMPORTANT NOTICE: This form of Notice of Exercise may only be used at such time as the Company has filed a Registration Statement with the Securities and Exchange Commission under which the issuance of the Shares for which this exercise is being made is registered and such Registration Statement remains effective.

Ladies and Gentlemen:

I hereby exercise my Stock Option to purchase _____ shares (the "Shares") of the common stock, \$0.0001 par value, of Hydrofarm Holdings Group, Inc. (the "Company"), at the exercise price of \$ _____ per share, pursuant to and subject to the terms of that Stock Option Grant Notice dated _____, 202__.

I understand the nature of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have consulted with competent tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option and the purchase and subsequent sale of the Shares.

I am paying the option exercise price for the Shares as follows:

Please issue the Shares (check one):

☐ to me; or

☐ to me and _____, as joint tenants with right of survivorship,

at the following address:

My mailing address for stockholder communications, if different from the address listed above, is:

Date: November 9, 2023

/s/ B.
John
Lindeman
B. John
Lindeman
Chief
Financial
Officer
(Principal
Financial
Officer)

Very truly yours,

Participant Signature

Print Name

Date

HYDROFARM HOLDINGS GROUP, INC.
Restricted Stock Unit Award Grant Notice
Restricted Stock Unit Award Grant under the Company’s 2020 Employee, Director, and
Consultant Equity Incentive Plan

- 1. Name of Participant:
- 2. Date of Grant of Restricted Stock Unit:
- 3. Maximum Number of Shares underlying
Restricted Stock Unit Award

4. Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, Director or Consultant of the Company or of an Affiliate on the applicable vesting:

[Insert Vesting Schedule]

The Company and the Participant acknowledge receipt of this Restricted Stock Unit Award Grant Notice and agree to the terms of the Restricted Stock Unit Agreement attached hereto and incorporated by reference herein, the Company's 2020 Employee, Director and Consultant Equity Incentive Plan and the terms of this Restricted Stock Unit Award as set forth above.

HYDROFARM HOLDINGS GROUP, INC.

By:

Name:

Title:

Participant:

HYDROFARM HOLDINGS GROUP, INC.

RESTRICTED STOCK UNIT AGREEMENT – INCORPORATED TERMS AND CONDITIONS

AGREEMENT (this "Agreement") made as of the date of grant set forth in the Restricted Stock Unit Award Grant Notice between Hydrofarm Holdings Group, Inc. (the "Company"), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the "Participant").

WHEREAS, the Company has adopted the 2020 Employee, Director and Consultant Equity Incentive Plan (the "Plan"), to promote the interests of the Company by providing an incentive for Employees, directors and Consultants of the Company and its Affiliates;

WHEREAS, pursuant to the provisions of the Plan, the Company desires to grant to the Participant restricted stock units ("RSUs") related to the Company's common stock, \$0.0001 par value per share ("Common Stock"), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; and

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

a. Grant of Award. The Company hereby grants to the Participant an award for the number of RSUs set forth in the Restricted Stock Unit Award Grant Notice (the "Award"). Each RSU represents a contingent entitlement of the Participant to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth herein and in the Plan, which is incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan.

b. Vesting of Award.

(i) Subject to the terms and conditions set forth in this Agreement and the Plan, the Award granted hereby shall vest as set forth in the Restricted Stock Unit Award Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan. On each vesting date set forth in the Restricted Stock Unit Award Grant Notice, the Participant shall be entitled to receive such number of shares of Common Stock equivalent to the number of RSUs as set forth in the Restricted Stock Unit Award Grant Notice provided that the Participant is employed or providing service to the Company or an Affiliate on such vesting date. Such shares of Common Stock shall thereafter be delivered by the Company to the Participant within five days of the applicable vesting date and in accordance with this Agreement and the Plan.

(ii) Except as otherwise set forth in this Agreement, if the Participant ceases to be employed or providing services for any reason by the Company or by an Affiliate (the

"Termination") prior to a vesting date set forth in the Restricted Stock Unit Award Grant Notice, then as of the date on which the Participant's employment or service terminates, all unvested RSUs shall immediately be forfeited to the Company and this Agreement shall terminate and be of no further force or effect.

c. Prohibitions on Transfer and Sale. This Award (including any additional RSUs received by the Participant as a result of stock dividends, stock splits or any other similar transaction affecting the Company's securities without receipt of consideration) shall not be transferable by the Participant otherwise than (i) by will or by the laws of descent and distribution, or (ii) pursuant to a qualified domestic relations order as defined by the Internal Revenue Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Except as provided in the previous sentence, the shares of Common Stock to be issued pursuant to this Agreement shall be issued, during the Participant's lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant's guardian or representative). This Award shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 3, or the levy of any attachment or similar process upon this Award shall be null and void.

d. Adjustments. The Plan contains provisions covering the treatment of RSUs and shares of Common Stock in a number of contingencies such as stock splits. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

e. Securities Law Compliance. The Participant specifically acknowledges and agrees that any sales of shares of Common Stock shall be made in accordance with the requirements of the Securities Act of 1933, as amended. The Company currently has an effective registration statement on file with the Securities and Exchange Commission with respect to the Common Stock to be granted hereunder. The Company intends to maintain this registration statement but has no obligation to do so. If the registration statement ceases to be effective for any reason, Participant will not be able to transfer or sell any of the shares of Common Stock issued to the Participant pursuant to this Agreement unless exemptions from registration or filings under applicable securities laws are available. Furthermore, despite registration, applicable securities laws may restrict the ability of the Participant to sell his or her Common Stock, including due to the Participant's affiliation with the Company. The Company shall not be obligated to either issue the Common Stock or permit the resale of any shares of Common Stock if such issuance or resale would violate any applicable securities law, rule or regulation.

f. Rights as a Stockholder. The Participant shall have no right as a stockholder, including voting and dividend rights, with respect to the RSUs subject to this Agreement.

g. Incorporation of the Plan. The Participant specifically understands and agrees that the RSUs and the shares of Common Stock to be issued under the Plan will be issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has

2

read and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference.

h. Tax Liability of the Participant and Payment of Taxes. The Participant acknowledges and agrees that any income or other taxes due from the Participant with respect to this Award or the shares of Common Stock to be issued pursuant to this Agreement or otherwise sold shall be the Participant's responsibility. Without limiting the foregoing, the Participant agrees that if under applicable law the Participant will owe taxes at each vesting date on the portion of the Award then vested the Company shall be entitled to immediate payment from the Participant of the

amount of any tax or other amounts required to be withheld by the Company by applicable law or regulation. Any taxes or other amounts due shall be paid, at the option of the Administrator as follows:

(i) through reducing the number of shares of Common Stock entitled to be issued to the Participant on the applicable vesting date in an amount, to the extent permitted by applicable law, sufficient to satisfy the federal, state, and local withholding tax requirements, both domestic and foreign, relating to such transaction, provided that such amount may not exceed the maximum statutory withholding rate. Fractional shares will not be retained to satisfy any portion of the Company's withholding obligation. Accordingly, the Participant agrees that in the event that the amount of withholding required would result in a fraction of a share being owed, that amount will be satisfied by withholding the fractional amount from the Participant's paycheck;

(ii) requiring the Participant to deposit with the Company an amount of cash equal to the amount determined by the Company to be required to be withheld for the Participant's total tax and other withholding obligations due and payable by the Company or otherwise withholding from the Participant's paycheck an amount equal to such amounts due and payable by the Company; or

(iii) if the Company believes that the sale of shares can be made in compliance with applicable securities laws, authorizing, at a time when the Participant is not in possession of material nonpublic information, the sale by the Participant on the applicable vesting date of such number of shares of Common Stock as the Company instructs a registered broker to sell to satisfy the Company's withholding obligation, after deduction of the broker's commission, and the broker shall be required to remit to the Company the cash necessary in order for the Company to satisfy its withholding obligation. To the extent the proceeds of such sale exceed the Company's withholding obligation the Company agrees to pay such excess cash to the Participant as soon as practicable. In addition, if such sale is not sufficient to pay the Company's withholding obligation the Participant agrees to pay to the Company as soon as practicable, including through additional payroll withholding, the amount of any withholding obligation that is not satisfied by the sale of shares of Common Stock. The Participant agrees to hold the Company and the broker harmless from all costs, damages or expenses relating to any such sale. The Participant acknowledges that the Company and the broker are under no obligation to arrange for such sale at any particular price. In connection with such sale of shares of Common Stock, the Participant shall execute any such documents requested by the broker in order to effectuate the sale of shares of Common Stock and payment of the withholding obligation to the Company. The Participant

3

acknowledges that this paragraph is intended to comply with Section 10b5-1(c)(1)(i)(B) under the Exchange Act.

4

The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.

i. Participant Acknowledgements and Authorizations. The Participant acknowledges the following:

(i) The Company is not by the Plan or this Award obligated to continue the Participant as an employee, director or consultant of the Company or an Affiliate.

(ii) The Plan is discretionary in nature and may be suspended or terminated by the Company at any time.

(iii) The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award under the Plan, benefits in lieu of awards or any other benefits in the future.

(iv) The Plan is a voluntary program of the Company and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting provisions and the purchase price, if any.

(v) The value of this Award is an extraordinary item of compensation outside of the scope of the Participant's employment or consulting contract, if any. As such the Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. The future value of the shares of Common Stock is unknown and cannot be predicted with certainty.

(vi) The Participant (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

j. Notices. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows:

If to the Company:

Hydrofarm Holdings Group, Inc.
2225 Huntington Drive
Fairfield, CA 94533
Attn: _____

5

If to the Participant at the address set forth on the Restricted Stock Unit Award Grant Notice or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given on the earliest of receipt, one business day following delivery by the sender to a recognized courier service, or three business days following mailing by registered or certified mail.

k. Assignment and Successors.

(i) This Agreement is personal to the Participant and without the prior written consent of the Company shall not be assignable by the Participant otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Participant's legal representatives.

(ii) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

l. Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of [], without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent to exclusive jurisdiction in the state of California and agree that such litigation shall be conducted in the state courts of the state of [] or the federal courts of the United States for the District of [].

m. Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is

impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby.

n. **Entire Agreement.** This Agreement, together with the Plan, constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement provided, however, in any event, this Agreement shall be subject to and governed by the Plan.

o. **Modifications and Amendments; Waivers and Consents.** The terms and provisions of this Agreement may be modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

6

p. **Section 409A.** The Award of RSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Section 409A of the Code as a "short term deferral" (as that term is used in the final regulations and other guidance issued under Section 409A of the Code, including Treasury Regulation Section 1.409A-1(b)(4)(i)), and shall be construed accordingly.

q. **Data Privacy.** By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options and the administration of the Plan; (ii) to the extent permitted by applicable law waives any data privacy rights he or she may have with respect to such information, and (iii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Exhibit 10.3

HYDROFARM HOLDINGS GROUP, INC.

Performance Stock Unit Award Grant Notice

Performance Stock Unit Award Grant under the Company's 2020 Employee, Director, and Consultant Equity Incentive Plan

1. Name of Participant:
2. Date of Grant of Performance Stock Unit:
3. Maximum Number of Shares underlying
Performance Stock Unit Award:
4. Vesting of Award: This Performance Stock Unit Award shall vest as follows provided the Participant is an Employee, Director or Consultant of the Company or of an Affiliate on the applicable vesting:

[Insert Vesting Schedule]

The Company and the Participant acknowledge receipt of this Performance Stock Unit Award Grant Notice and agree to the terms of the Performance Stock Unit Agreement attached hereto and incorporated by reference herein, the Company's 2020 Employee, Director and Consultant Equity Incentive Plan and the terms of this Performance Stock Unit Award as set forth above.

HYDROFARM HOLDINGS GROUP, INC.

By:

Name:

Title:

Participant:

HYDROFARM HOLDINGS GROUP, INC.

PERFORMANCE STOCK UNIT AGREEMENT – INCORPORATED TERMS AND CONDITIONS

AGREEMENT (this "Agreement") made as of the date of grant set forth in the Performance Stock Unit Award Grant Notice between Hydrofarm Holdings Group, Inc. (the "Company"), a Delaware corporation, and the individual whose name appears on the Performance Stock Unit Award Grant Notice (the "Participant").

WHEREAS, the Company has adopted the 2020 Employee, Director and Consultant Equity Incentive Plan (the "Plan"), to promote the interests of the Company by providing an incentive for Employees, directors and Consultants of the Company and its Affiliates;

WHEREAS, pursuant to the provisions of the Plan, the Company desires to grant to the Participant Performance stock units ("PSUs") related to the Company's common stock, \$0.0001 par value per share ("Common Stock"), in accordance with the provisions of the Plan, all on the terms and conditions hereinafter set forth; and

WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. **Grant of Award.** The Company hereby grants to the Participant an award for the number of PSUs set forth in the Performance Stock Unit Award Grant Notice (the "Award"). Each PSU represents a contingent entitlement of the Participant to receive one share of Common Stock, on the terms and conditions and subject to all the limitations set forth herein and in the Plan, which is incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan.

2. **Vesting of Award.**

(a) Subject to the terms and conditions set forth in this Agreement and the Plan, the Award granted hereby shall vest as set forth in the Performance Stock Unit Award Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan. On each vesting date set forth in the Performance Stock Unit Award Grant Notice, the Participant shall be entitled to receive such number of shares of Common Stock equivalent to the number of PSUs as set forth in the Performance Stock Unit Award Grant Notice provided that the Participant is employed or providing service to the Company or an Affiliate on such vesting date. Such shares of Common Stock shall thereafter be delivered by the Company to the Participant within five days of the applicable vesting date and in accordance with this Agreement and the Plan.

(b) Except as otherwise set forth in this Agreement, if the Participant ceases to be employed or providing services for any reason by the Company or by an Affiliate (the "Termination") prior to a vesting date set forth in the Performance Stock Unit Award Grant Notice, then as of the date on which the Participant's employment or service terminates, all unvested PSUs shall immediately be forfeited to the Company and this Agreement shall terminate and be of no further force or effect.

3. **Prohibitions on Transfer and Sale.** This Award (including any additional PSUs received by the Participant as a result of stock dividends, stock splits or any other similar transaction affecting the Company's securities without receipt of consideration) shall not be transferable by the Participant otherwise than (i) by will or by the laws of descent and distribution, or (ii) pursuant to a qualified domestic relations order as defined by the Internal Revenue Code or Title I of the Employee Retirement Income Security Act or the rules thereunder.

Except as provided in the previous sentence, the shares of Common Stock to be issued pursuant to this Agreement shall be issued, during the Participant's lifetime, only to the Participant (or, in the event of legal incapacity or incompetence, to the Participant's guardian or representative). This Award shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of this Award or of any rights granted hereunder contrary to the provisions of this Section 3, or the levy of any attachment or similar process upon this Award shall be null and void.

4. Adjustments. The Plan contains provisions covering the treatment of PSUs and shares of Common Stock in a number of contingencies such as stock splits. Provisions in the Plan for adjustment with respect to this Award and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.

5. Securities Law Compliance. The Participant specifically acknowledges and agrees that any sales of shares of Common Stock shall be made in accordance with the requirements of the Securities Act of 1933, as amended. The Company currently has an effective registration statement on file with the Securities and Exchange Commission with respect to the Common Stock to be granted hereunder. The Company intends to maintain this registration statement but has no obligation to do so. If the registration statement ceases to be effective for any reason, Participant will not be able to transfer or sell any of the shares of Common Stock issued to the Participant pursuant to this Agreement unless exemptions from registration or filings under applicable securities laws are available. Furthermore, despite registration, applicable securities laws may restrict the ability of the Participant to sell his or her Common Stock, including due to the Participant's affiliation with the Company. The Company shall not be obligated to either issue the Common Stock or permit the resale of any shares of Common Stock if such issuance or resale would violate any applicable securities law, rule or regulation.

6. Rights as a Stockholder. The Participant shall have no right as a stockholder, including voting and dividend rights, with respect to the PSUs subject to this Agreement.

7. Incorporation of the Plan. The Participant specifically understands and agrees that the PSUs and the shares of Common Stock to be issued under the Plan will be issued to the Participant pursuant to the Plan, a copy of which Plan the Participant acknowledges he or she has read and understands and by which Plan he or she agrees to be bound. The provisions of the Plan are incorporated herein by reference.

8. Tax Liability of the Participant and Payment of Taxes. The Participant acknowledges and agrees that any income or other taxes due from the Participant with respect to this Award or the shares of Common Stock to be issued pursuant to this Agreement or otherwise sold shall be the Participant's responsibility. Without limiting the foregoing, the Participant agrees that if under applicable law the Participant will owe taxes at each vesting date on the portion of the Award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax or other amounts required to be withheld by the Company by applicable law or regulation. Any taxes or other amounts due shall be paid, at the option of the Administrator as follows:

(a) through reducing the number of shares of Common Stock entitled to be issued to the Participant on the applicable vesting date in an amount sufficient to satisfy the federal, state, and local withholding tax requirements, both domestic and foreign, relating to such transaction, provided that such amount may not exceed the maximum statutory withholding rate. Fractional shares will not be retained to satisfy any portion of the Company's withholding obligation. Accordingly, the Participant agrees that in the event that the amount of withholding required would result in a fraction of a share being owed, that amount will be satisfied by withholding the fractional amount from the Participant's paycheck;

(b) requiring the Participant to deposit with the Company an amount of cash, or otherwise, to the extent permitted by applicable law, withholding from the Participant's paycheck such amount, sufficient to satisfy the federal, state, and local withholding tax requirements, both domestic and foreign, relating to such transaction, provided that such amount may not exceed the maximum statutory withholding rate; or

(c) if the Company believes that the sale of shares can be made in compliance with applicable securities laws, authorizing, at a time when the Participant is not in possession of material nonpublic information, the sale by the Participant on the applicable vesting date of such number of shares of Common Stock as the Company instructs a registered broker to sell to satisfy the Company's withholding obligation, after deduction of the broker's commission, and the broker shall be required to remit to the Company the cash necessary in order for the Company to satisfy its withholding obligation. To the extent the proceeds of such sale exceed the Company's withholding obligation the Company agrees to pay such excess cash to the Participant as soon as practicable. In addition, if

such sale is not sufficient to pay the Company's withholding obligation the Participant agrees to pay to the Company as soon as practicable, including through additional payroll withholding, the amount of any withholding obligation that is not satisfied by the sale of shares of Common Stock. The Participant agrees to hold the Company and the broker harmless from all costs, damages or expenses relating to any such sale. The Participant acknowledges that the Company and the broker are under no obligation to arrange for such sale at any particular price. In connection with such sale of shares of Common Stock, the Participant shall execute any such documents requested by the broker in order to effectuate the sale of shares of Common Stock and payment of the withholding obligation to the Company. The Participant acknowledges that this paragraph is intended to comply with Section 10b5-1(c)(1)(i)(B) under the Exchange Act.

The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.

9. Participant Acknowledgements and Authorizations.

The Participant acknowledges the following:

(a) The Company is not, by the Plan or this Award, obligated to continue the Participant as an employee, director or consultant of the Company or an Affiliate.

(b) The Plan is discretionary in nature and may be suspended or terminated by the Company at any time.

(c) The grant of this Award is considered a one-time benefit and does not create a contractual or other right to receive any other award under the Plan, benefits in lieu of awards or any other benefits in the future.

(d) The Plan is a voluntary program of the Company and future awards, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of any grant, the amount of any award, vesting provisions and the purchase price, if any.

(e) The value of this Award is an extraordinary item of compensation outside of the scope of the Participant's employment or consulting contract, if any. As such the Award is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. The future value of the shares of Common Stock is unknown and cannot be predicted with certainty.

(f) The Participant (i) authorizes the Company and each Affiliate and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of the Award and the administration of the Plan; and (ii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

10. Notices. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows:

If to the Company:

Hydrofarm Holdings Group, Inc. 2225 Huntington Drive
Fairfield, California 94533 Attn: Shanna Peterson

If to the Participant at the address set forth on the Performance Stock Unit Award Grant Notice or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given on the earliest of receipt, one business day following delivery by the sender to a recognized courier service, or three business days following mailing by registered or certified mail.

11. Assignment and Successors.

(a) This Agreement is personal to the Participant and without the prior written consent of the Company shall not be assignable by the Participant otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Participant's legal representatives.

(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

12. Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, whether at law or in equity, the parties hereby consent

to exclusive jurisdiction in the state of [] and agree that such litigation shall be conducted in the state courts of the state of [] or the federal courts of the United States for the District of [].

13. Severability. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then such provision or provisions shall be modified to the extent necessary to make such provision valid and enforceable, and to the extent that this is impossible, then such provision shall be deemed to be excised from this Agreement, and the validity, legality and enforceability of the rest of this Agreement shall not be affected thereby.

14. Entire Agreement. This Agreement, together with the Plan, constitutes the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict the express terms and provisions of this Agreement provided, however, in any event, this Agreement shall be subject to and governed by the Plan.

15. Modifications and Amendments; Waivers and Consents. The terms and provisions of this Agreement may be modified or amended as provided in the Plan. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the

party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.

16. Section 409A. The Award of PSUs evidenced by this Agreement is intended to be exempt from the nonqualified deferred compensation rules of Section 409A of the Code as a "short term deferral" (as that term is used in the final regulations and other guidance issued under Section 409A of the Code, including Treasury Regulation Section 1.409A-1(b)(4)(i)), and shall be construed accordingly.

17. Data Privacy. By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options and the administration of the Plan; (ii) to the extent permitted by applicable law waives any data privacy rights he or she may have with respect to such information, and (iii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, William Toler, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydrofarm Holdings Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

- a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023 May 14, 2024

By: /s/ William Toler
 William Toler
 Chief Executive Officer
 (Principal Executive Officer)

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, B. John Lindeman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Hydrofarm Holdings Group, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023 May 14, 2024

By: /s/ B. John Lindeman

B. John Lindeman

Executive Vice President & Chief Financial Officer

(Principal Financial Officer)

Exhibit 32.1

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Hydrofarm Holdings Group, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report for the quarter ended September 30, 2023 March 31, 2024 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 9, 2023 May 14, 2024

/s/ William Toler

William Toler

Chief Executive Officer

(Principal Executive Officer)

Exhibit 32.2

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Hydrofarm Holdings Group, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report for the quarter ended September 30, 2023 March 31, 2024 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations

of the Company.

Dated: November 9, 2023 May 14, 2024

/s/ B. John Lindeman
B. John Lindeman
Executive Vice President & Chief Financial Officer
(Principal Financial Officer)

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.